tegafur has been researched along with Colorectal Cancer in 428 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 9.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| "Fluorouracil and leucovorin combined with oxaliplatin or irinotecan plus bevacizumab (Bmab) or cetuximab (Cmab) are now widely accepted treatment options as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC)." | 9.34 | Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. ( Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N, 2020) |
| "Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)." | 9.27 | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018) |
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 9.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)." | 9.27 | A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018) |
| "Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan." | 9.22 | S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). ( Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A, 2016) |
| "Irinotecan plus S-1 (IRIS) is the only oral fluoropyrimidine-based regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for metastatic colorectal cancer (mCRC) patients." | 9.22 | Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. ( Goda, F; Goji, T; Kawamoto, S; Kimura, M; Kimura, T; Kitamura, S; Miyamoto, H; Muguruma, N; Negoro, Y; Niitsu, Y; Okahisa, T; Okamoto, K; Sakamoto, K; Shimoyama, R; Takaoka, T; Takayama, T; Tsuji, A; Yano, H; Yoshizaki, K, 2016) |
| "Oral uracil-tegafur and leucovorin (UFT/LV) therapy for elderly patients with metastatic colorectal cancer (mCRC) requires careful handling in Western countries because of a high incidence (≥20 %) of grade 3 diarrhea." | 9.20 | Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study. ( Hyodo, I; Maeba, T; Matsumoto, T; Mizuta, M; Moriwaki, T; Nishina, T; Takahashi, I; Tsuji, A; Watanabe, R; Watanabe, Y, 2015) |
| "The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint." | 9.20 | A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015) |
| "Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)." | 9.20 | Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 9.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy." | 9.20 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015) |
| "To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)." | 9.19 | Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014) |
| "We conducted a clinical trial of a seven-peptide vaccine in combination with tegafur-uracil/Leucovorin for advanced colorectal cancer." | 9.19 | [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer]. ( Hida, J; Inoue, K; Kogita, A; Okuno, K; Sugiura, F; Sukegawa, Y; Yoshioka, Y, 2014) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 9.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer." | 9.17 | A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H, 2013) |
| "To identify the genes and clinical parameters associated with efficacy of uracil and tegafur/leucovorin (UFT/LV) chemotherapy in colorectal cancer (CRC), we compared the levels of reduced folate in tumors between patients receiving LV and those not receiving LV (study I), and explored the changes in the expression levels of 14 genes after two weeks of UFT/LV chemotherapy in 73 patients with CRC (study II)." | 9.17 | Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer. ( Kamijo, A; Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2013) |
| "Forty-two chemo-naive patients with metastatic colorectal cancer (mCRC) were planned to be enrolled and be treated with irinotecan 150 mg m(-2) followed by oxaliplatin 85 mg m(-2) on day 1 and S-1 80 mg m(-2) per day from day 1 to 14 every 3 weeks." | 9.17 | S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. ( Baek, JY; Jung, KH; K Shim, E; Kim, SY; Kong, SY; S Hong, Y; Shin, A, 2013) |
| "We have reported, in a randomized, controlled study, that tegafur-uracil(UFT)and protein-bound polysaccharide K(PSK)combination therapy significantly improves the 5-year disease-free survival rate and reduces the risk of recurrence compared to UFT alone for Stage II or III colorectal cancer." | 9.17 | [Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K]. ( Hirai, K; Kawate, S; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Toya, H; Yoshinari, D, 2013) |
| "This study attempted to determine the therapeutic dosage of irinotecan and S-1 (IRIS) as a second-line treatment for colorectal cancer (CRC)." | 9.17 | Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer. ( Akazawa, K; Funakoshi, K; Hasegawa, J; Hatakeyama, K; Maruyama, S; Okada, T; Takii, Y; Tani, T; Yamazaki, T, 2013) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer." | 9.17 | Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. ( Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K, 2013) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 9.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "Fluorouracil (5-FU) plus irinotecan combined with bevacizumab has significant activity in metastatic colorectal cancer (mCRC), but S-1 has become a substitute for continuous infusion of 5-FU and has a very low incidence of hand-foot syndrome." | 9.16 | Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Ichikawa, Y; Kato, K; Matsumoto, H; Shimada, Y; Yamada, Y; Yamaguchi, T, 2012) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 9.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "We investigated the efficacy and safety of the combination of irinotecan (CPT-11) and S-1 (IRIS regimen) as a first-line treatment in patients with metastatic colorectal cancer." | 9.16 | A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Ryoo, BY; Ryu, MH; Shin, JG, 2012) |
| "Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B)." | 9.16 | Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial. ( Hasegawa, H; Hisa, A; Kitagawa, Y; Ohishi, T; Okabayashi, K; Watanabe, M, 2012) |
| "The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer." | 9.16 | Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Yamada, Y, 2012) |
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 9.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| "Capecitabine plus oxaliplatin (CapeOX) is one of the reference doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer." | 9.16 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2012) |
| "To determine the efficacy and tolerance of irinotecan in combination with S-1 (IRIS) for patients whose disease progressed after treatment with an oxaliplatin-based therapy for colorectal cancer (CRC)." | 9.15 | Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. ( Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY, 2011) |
| "To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases." | 9.15 | Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011) |
| "To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer." | 9.15 | A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 9.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "Three-drug combination of fluoropyrimidine, irinotecan and oxaliplatin has shown survival benefits in patients with metastatic colorectal cancer (mCRC)." | 9.14 | A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. ( Choi, HS; Hong, CW; Hong, YS; Jeong, SY; Jung, KH; Kim, BC; Kim, DY; Kim, SY; Park, JW; Sohn, DK, 2009) |
| "The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan (CPT-11) plus S-1 in advanced colorectal cancer." | 9.14 | A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K, 2009) |
| "Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest." | 9.14 | Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009) |
| "A 24-hour infusion of irinotecan combined with UFT/LV is feasible and active for metastatic colorectal cancer." | 9.14 | Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A, 2009) |
| "To determine the efficacy and tolerability of oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced colorectal cancer." | 9.14 | Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N, 2009) |
| "The combination of oral uracil/tegafur (UFT) plus leucovorin (LV) is widely accepted as adjuvant chemotherapy for stages II and III of colorectal cancer." | 9.14 | Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients. ( Furuhata, T; Hirata, K; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K, 2009) |
| "Both irinotecan (CPT-11) and S-1 are active against colorectal cancer; however, as S-1 is a prodrug of 5-fluorouracil (5-FU), 5-FU and its metabolites might inhibit the antitumour effect of CPT-11." | 9.14 | Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. ( Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Otsuka, K; Sakayori, N; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, S; Yoshioka, T, 2009) |
| " This phase I study was performed to determine the recommended dosage (RD) of metronomic chemotherapy using oral fluoropyrimidine S-1 plus weekly irinotecan (CPT-11) in patients with previously untreated advanced or recurrent colorectal cancer." | 9.14 | Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer. ( Akagi, Y; Ishibashi, N; Mori, S; Ogata, Y; Sasatomi, T; Shirouzu, K, 2009) |
| "We carried out this study to examine the health-related quality of life (HRQOL) of patients with advanced colorectal cancer treated with the oral fluoropyrimidine S-1 plus irinotecan (CPT-11)." | 9.14 | Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11). ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Tsunoda, Y; Watanabe, M; Yasuda, N, 2010) |
| "A combination of irinotecan with continuous infusional 5-fluorouracil (5-FU) is the standard treatment for advanced colorectal cancer." | 9.14 | A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Tsuchida, K; Yamamoto, N, 2010) |
| "Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer." | 9.14 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer." | 9.14 | Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. ( Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Futami, K; Kinugawa, N; Kusaba, H; Mibu, R; Mitsugi, K; Nakano, S; Sakai, K; Tanaka, R; Tanaka, S; Ueki, T, 2010) |
| "A randomized controlled trial was conducted to determine whether pathologic necrosis in response to preoperative treatment with uracil-tegafur(UFT) could be used to identify patients with colorectal cancer most likely to benefit from postoperative adjuvant therapy with the drug." | 9.13 | Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial. ( Fujii, M; Kochi, M; Takayama, T, 2008) |
| "Tegafur-uracil (UFT) plus leucovorin (LV, folinic acid) with alternating irinotecan and oxaliplatin were effective and well tolerated in patients with metastatic colorectal cancer (mCRC) in a phase I study." | 9.13 | Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Waddell, T; Wilson, G, 2008) |
| "To evaluate the efficacy and safety of irinotecan combined with UFT for untreated and pretreated metastatic colorectal cancer." | 9.13 | Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S, 2008) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 9.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 9.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| "This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens." | 9.12 | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. ( Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC, 2006) |
| "The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer." | 9.12 | Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G, 2007) |
| ") irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC)." | 9.12 | Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. ( Artru, P; Bennouna, J; Bugat, R; Delord, JP; Desseigne, F; Douillard, JY; Faroux, R; François, E; Husseini, F; Naman, H; Perrier, H; Piedbois, P; Smith, D, 2007) |
| "To determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan plus S-1 in advanced colorectal cancer." | 9.12 | Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Nakao, K; Narita, K; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K; Yasuda, N, 2007) |
| "To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer." | 9.12 | Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. ( Beatty, PA; Benson, AB; Hochster, HS; Luo, W; Lyman, BT; Mulcahy, M; Popa, EC, 2007) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 9.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| " We investigated the benefits of oral protein-bound polysaccharide K (PSK) with tegafur/uracil (UFT) as an adjuvant in stage II and III colorectal cancer." | 9.11 | Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. ( Ikeya, T; Ishikawa, H; Iwazaki, S; Kakinuma, S; Kawate, S; Kusaba, T; Morishita, Y; Nakajima, T; Nakamura, S; Ohwada, S; Roppongi, T; Takahashi, T; Yokomori, T, 2004) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 9.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "To compare the efficacy, toxicities, and pharmacokinetics of an oral regimen consisting of uracil/tegafur (UFT) and leucovorin (LV) between Japanese patients and patients in the United States with previously untreated metastatic colorectal cancer." | 9.11 | Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. ( Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004) |
| " infusion; days 1, 8 and 15) combined with UFT (oral combination of tegafur and uracil) 200 mg/m2/day plus leucovorin (LV) 45 mg/m2/day (both divided into three separate oral doses every 8 h, days 1-21) every 4 weeks as first-line chemotherapy of metastatic colorectal cancer (CRC)." | 9.11 | Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. ( Alfonso, PG; Castañon, C; Cerezuela, P; Cruz, JJ; González, E; López-Mateos, Y; Méndez, M; Pujol, E, 2005) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 9.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "This randomised, open-label trial compared oral tegafur (FT)/leucovorin (LV) with the intravenous bolus 5-fluorouracil (5-FU)/LV as first-line chemotherapy for advanced colorectal cancer (CRC)." | 9.11 | Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. ( Arcusa, A; Batiste-Alentorn, E; Boleda, M; Campos, JM; Cirera, L; de Mendizábal, EV; de Olaguer, JP; Escudero, P; Galan, A; Guasch, I; Losa, F; Manzano, H; Méndez, M; Nogué, M; Saigí, E; Salud, A; Vicente, P, 2005) |
| "The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profile and response rate of the oral 5-fluorouracil prodrug UFT (tegafur/uracil) and leucovorin (LV) in combination with irinotecan in patients with advanced or metastatic colorectal cancer." | 9.10 | A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. ( Bailey, SM; Campbell, S; Cunningham, D; Glasspool, R; Hill, M; Macham, MA; Mackay, HJ; Martin, C; Massey, A; Price, T; Twelves, C; Uzzel, M, 2003) |
| "Adjuvant therapy using a combination of oral protein-bound polysaccharide K and tegafur/uracil is highly effective in preventing the recurrence of colorectal cancer in Stage II or III patients, and increases overall survival in pathological TNM Stage III." | 9.10 | Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. ( Ikeya, T; Kawashima, Y; Kawate, S; Kusaba, T; Morishita, Y; Nakajima, T; Nakamura, S; Ohwada, S; Roppongi, T; Takahashi, T; Yokomori, T, 2003) |
| ") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options." | 9.10 | Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002) |
| "The objective of this study was to evaluate the activity and toxicity of tegafur and uracil (UFT; 1:4 molar ratio) plus leucovorin (LV) in patients with advanced colorectal cancer." | 9.09 | Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial. ( Antón-Torres, A; Aparicio, J; Aranda, E; Bretón, JJ; Carrato, A; Díaz-Rubio, E; Fernández-Martos, C; Navarro, M; Rivera, F; Sastre, J, 2001) |
| "This phase I trial combining UFT plus oral calcium folinate (Orzel) with irinotecan (CPT-11) (Camptosar) for the treatment of patients with advanced or metastatic colorectal cancer will open shortly." | 9.09 | UFT plus calcium folinate/irinotecan in colorectal cancer. ( Twelves, C, 1999) |
| "The aim of this study was to clarify whether increased 5-fluorouracil (5-FU) uptake by tumor tissue following preoperative UFT administration is a prognostic factor after surgery in colorectal cancer patients." | 9.09 | Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor. ( Ayabe, H; Eida, K; Furukawa, M; Ino, M; Ishikawa, H; Kunisaki, T; Nakagoe, T; Nakamura, Y; Nogawa, T; Sawai, T; Tobinaga, K; Tsuji, T, 2000) |
| "UFT (with leucovorin) and irinotecan both have single-agent activity in colorectal cancer, with non-cross-resistant mechanisms of action." | 9.09 | UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. ( Hill, M; Price, T, 2000) |
| "This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer." | 9.09 | UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer. ( Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G, 2000) |
| "The aim of the study was to investigate the possibility of dual modulation of UFT with leucovorin and hydroxyurea in a phase II trial of metastatic colorectal cancer." | 9.09 | Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer. ( Aabo, K; Hansen, F; Jakobsen, A; Pfeiffer, P; Sandberg, E, 2001) |
| "Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 9.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
| "The results of this study show that an all-oral regimen of tegafur and leucovorin can obtain biochemical modulation, with a significant response rate, in patients with advanced colorectal carcinoma." | 9.08 | Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. ( Antón, I; Arcusa, A; Batiste-Alentorn, E; Boleda, M; Nogué, M; Saigí, E; Seguí, MA, 1998) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 8.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 8.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| "5-Fluorouracil (5-FU) administered in several schedules since its introduction in 1957 continues to be an integral part of standard first-line therapy for colorectal cancer." | 8.82 | The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. ( Beretta, GD; Labianca, R; Milesi, L; Mosconi, S, 2004) |
| "We evaluated the pharmacokinetics and pharmacodynamics/toxicodynamics of uracil-tegafur (UFT) after multiple administrations in colorectal cancer (CRC) model rats, and applied a pharmacometric approach to describe the time-course alterations of plasma 5-FU concentrations and tumor shrinkage." | 8.31 | A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model. ( Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023) |
| "This study suggests that tegafur/uracil plus leucovorin is a feasible adjuvant chemotherapy regimen for patients with stage II colorectal cancer after curative surgical treatment." | 8.31 | Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan. ( Chen, HH; Fan, CW; Liao, CK; Liaw, YW; Liu, YH; Tseng, WK; Yeh, CY; Yu, YL, 2023) |
| "Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer." | 7.91 | Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. ( Hsu, TC; Wang, CC, 2019) |
| "Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy." | 7.85 | Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017) |
| "This study sought to compare UFT/LV with capecitabine as adjuvant chemotherapy for the treatment of stage III colorectal cancer." | 7.83 | [Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer]. ( Maruyama, T; Okumura, M; Sako, A; Ueda, K; Yasuda, K, 2016) |
| "To analyze the therapeutic actions of tegafur gimeracil oteracil combined with oxaliplatin for treating patients with advanced colorectal cancer, and its effects on the K-ras gene mutation and the CK20 mRNA." | 7.81 | Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer. ( Ren, J; Wei, H; Yang, ZH; Yi, LJ; Zheng, JH, 2015) |
| "5-Fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) therapy and 5-FU, leucovorin, and irinotecan (FOLFIRI) therapy are standard chemotherapies to treat advanced/recurrent colorectal cancer." | 7.80 | Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer. ( Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014) |
| "The effectiveness of 5-fluorouracil (5-FU)-based adjuvant chemotherapy is reported in patients with colorectal cancer (CRC), but the usefulness of 5-FU metabolic enzymes as predictive biomarkers of the efficacy of this chemotherapy remains unclear." | 7.80 | Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. ( Hasegawa, H; Ishii, Y; Kitagawa, Y; Okabayashi, K; Shigeta, K, 2014) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 7.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "To identify useful predictive factors for the response to 5-fluorouracil (5-FU)/leucovorin (LV) and oral uracil and tegafur (UFT)/LV chemotherapy among patients with colorectal cancer, we investigated the association between the gene expression levels of pyrimidine and folate metabolism-related enzymes in colorectal cancer (CRC) tissues and the response to UFT/LV neoadjuvant chemotherapy." | 7.78 | Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. ( Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2012) |
| "The purpose of the study was to evaluate the efficacy and tolerability of S-1 monotherapy in metastatic colorectal cancer (CRC) patients who have failed the standard oxaliplatin-based or irinotecan-based chemotherapy." | 7.77 | Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy. ( Kang, WK; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, SY, 2011) |
| "Overall health-related quality of life did not deteriorate during adjuvant chemotherapy with oral uracil/tegafur plus leucovorin in patients with colorectal cancer, despite the effect from surgical damage, whereas the development of Grade 3 toxicities negatively affected on short-term health-related quality of life." | 7.76 | Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| "To establish the sufficient therapy for elderly colorectal cancer patients, we retrospectively compared postoperative Tegafur/Uracil (UFT; Taiho Pharmaceutical Co." | 7.75 | Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. ( Takashima, S; Yoshitani, S, 2009) |
| "Chemotherapy with irinotecan (CPT-11) or oxaliplatin (l-OHP) in combination with infusional 5-fluorouracil (5-FU) and their cross-over as second-line therapies are standard treatments for metastatic colorectal cancer (MCRC)." | 7.75 | Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. ( Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2009) |
| " This study was conducted to examine changes in DPD activity in peripheral mononuclear cells (PMNC) during long-term treatment with oral uracil and tegafur (UFT) for colorectal cancer." | 7.74 | Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. ( Ishikawa, K; Kamijo, A; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, Y; Yasuda, S, 2007) |
| "We report two cases of recurrent colorectal cancer in two patients who were treated successfully with a combined oral chemotherapeutic agent folinate/tegafur/uracil (UFT/LV) dosage." | 7.74 | [Two cases of recurrent colorectal cancer treated successfully with folinate/tegafur/uracil (UFT/LV) chemotherapy on an outpatient basis]. ( Hosotaki, K; Shimamoto, M; Tabira, Y; Tamori, Y, 2008) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 7.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| "The purpose of this study was to examine the relation between tumoral expression of dihydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of the degradation pathway 5-fluorouracil (5-FU), and the efficacy of 5-FU based chemotherapy for colorectal cancer." | 7.72 | [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. ( Hashimoto, D; Inokuma, S; Ishida, H; Nakada, H; Ohsawa, T; Shirakawa, K; Yamada, H; Yokoyama, M, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 7.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "(1) The standard chemotherapy for metastatic colorectal cancer is intravenous fluorouracil combined with calcium folinate." | 7.71 | Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages. ( , 2002) |
| "In order to elucidate the effect of tumor vascularity on a various regimens concentration in tumor tissue, correlation among tegafur, 5-fluorouracil (5-FU), uracil concentrations in tissue and the microangiography were examined in 27 patients with colorectal cancer after preoperative administration of UFT (400 mg/day for 7 days)." | 7.68 | [Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer]. ( Ishikawa, H; Kusano, H; Miyashita, K; Nakazaki, T; Ogawa, T; Shimizu, T; Shimoyama, T; Yasutake, T; Yoshida, A; Yoshida, K, 1993) |
| " UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer." | 7.68 | [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992) |
| " In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with bevacizumab for a similar population are reported." | 6.82 | Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU ( Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016) |
| "Irinotecan (125 mg/m(2)) was administered as a 24-hour infusion on days 1 and 15, S-1 (80 mg/m(2)) was administered orally on days 1-14, and bevacizumab (5." | 6.80 | A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ( Kamijo, A; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A, 2015) |
| "8% and grade 3 or higher adverse events occurred in 12." | 6.79 | A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study. ( Hasegawa, K; Ijichi, M; Kawasaki, S; Kokudo, N; Koyama, H; Makuuchi, M; Miyagawa, S; Oba, M; Saiura, A; Takayama, T; Teruya, M; Yamamoto, J; Yoshimi, F, 2014) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 6.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "Patients with advanced or metastatic colorectal cancer (CRC) received: UFT 300 mg/m(2), LV 75 mg/body and CPT-11 150 mg/m(2) (UFT and LV given on days 1-14, and CPT-11 on day 1, every 3 weeks)." | 6.74 | A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. ( Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y, 2009) |
| "This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX)." | 6.73 | Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. ( Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N, 2007) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 6.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "Colorectal cancer is usually diagnosed in elderly patients." | 6.71 | Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. ( Blanco, G; Bordonaro, R; Cordio, S; Manzione, L; Reggiardo, G; Rosati, G; Tucci, A, 2005) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 6.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| "79 patients with measurable advanced colorectal cancer (CRC) and no prior chemotherapy were included." | 6.68 | Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. ( Blanco, E; Colmenarejo, A; de la Gándara, I; Espinosa, E; Feliu, J; García-Girón, C; Garrido, P; González-Barón, M; Juárez, F; Martínez-Martínez, B, 1995) |
| "Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours." | 6.40 | Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. ( Hoff, PM; Lassere, Y; Pazdur, R, 1999) |
| "Stage II colorectal cancer has a relatively good prognosis." | 5.62 | Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer. ( Chen, TC; Jeng, YM; Liang, JT, 2021) |
| "At the age of 78 advanced colorectal cancer (stage IIIa) was diagnosed and laparoscopic-assisted colectomy was performed." | 5.56 | Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report. ( Fujii, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Imafuku, A; Kawada, M; Mizuno, H; Ohashi, K; Sawa, N; Sekine, A; Suwabe, T; Toriu, N; Ubara, Y; Yamanouchi, M, 2020) |
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| " Coadministration of S-1 changed the pharmacokinetic behavior of CPT-11 and its metabolites." | 5.35 | Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer. ( Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K, 2009) |
| "Fluorouracil and leucovorin combined with oxaliplatin or irinotecan plus bevacizumab (Bmab) or cetuximab (Cmab) are now widely accepted treatment options as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.34 | Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. ( Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N, 2020) |
| "When tegafur was injected, the concentration of 5-FU in cancer tissue or lymphnodes was significantly higher than in normal tissue." | 5.30 | [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer]. ( Inamura, Y; Kanemitsu, T; Kojima, T; Miyashita, A; Naruse, T; Owa, Y; Suzumura, K, 1998) |
| "Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)." | 5.27 | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018) |
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 5.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)." | 5.27 | A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018) |
| "Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan." | 5.22 | S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). ( Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A, 2016) |
| "Irinotecan plus S-1 (IRIS) is the only oral fluoropyrimidine-based regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for metastatic colorectal cancer (mCRC) patients." | 5.22 | Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. ( Goda, F; Goji, T; Kawamoto, S; Kimura, M; Kimura, T; Kitamura, S; Miyamoto, H; Muguruma, N; Negoro, Y; Niitsu, Y; Okahisa, T; Okamoto, K; Sakamoto, K; Shimoyama, R; Takaoka, T; Takayama, T; Tsuji, A; Yano, H; Yoshizaki, K, 2016) |
| "A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer." | 5.22 | Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer. ( Kaiho, T; Kobayashi, S; Koda, K; Kosugi, C; Maruyama, T; Matsubara, H; Miyauchi, H; Takiguchi, N, 2016) |
| "Oral uracil-tegafur and leucovorin (UFT/LV) therapy for elderly patients with metastatic colorectal cancer (mCRC) requires careful handling in Western countries because of a high incidence (≥20 %) of grade 3 diarrhea." | 5.20 | Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study. ( Hyodo, I; Maeba, T; Matsumoto, T; Mizuta, M; Moriwaki, T; Nishina, T; Takahashi, I; Tsuji, A; Watanabe, R; Watanabe, Y, 2015) |
| "The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint." | 5.20 | A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015) |
| "Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)." | 5.20 | Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 5.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy." | 5.20 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015) |
| " This study investigated the impact of KRAS, NRAS, BRAF, PI3KCA and TP53 status on outcome of elderly metastatic colorectal cancer patients enrolled in TEGAFOX-E (cetuximab, oxaliplatin and oral uracil/ftorafur--UFT) phase II study." | 5.19 | Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. ( Bajetta, E; Beretta, E; Bertan, C; Biondani, P; Carbone, C; Di Bartolomeo, M; Dotti, KF; Lampis, A; Passalacqua, R; Perrone, F; Pietrantonio, F; Pilotti, S; Rimassa, L, 2014) |
| "To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)." | 5.19 | Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014) |
| "We conducted a clinical trial of a seven-peptide vaccine in combination with tegafur-uracil/Leucovorin for advanced colorectal cancer." | 5.19 | [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer]. ( Hida, J; Inoue, K; Kogita, A; Okuno, K; Sugiura, F; Sukegawa, Y; Yoshioka, Y, 2014) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 5.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer." | 5.17 | A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H, 2013) |
| "To identify the genes and clinical parameters associated with efficacy of uracil and tegafur/leucovorin (UFT/LV) chemotherapy in colorectal cancer (CRC), we compared the levels of reduced folate in tumors between patients receiving LV and those not receiving LV (study I), and explored the changes in the expression levels of 14 genes after two weeks of UFT/LV chemotherapy in 73 patients with CRC (study II)." | 5.17 | Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer. ( Kamijo, A; Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2013) |
| "Forty-two chemo-naive patients with metastatic colorectal cancer (mCRC) were planned to be enrolled and be treated with irinotecan 150 mg m(-2) followed by oxaliplatin 85 mg m(-2) on day 1 and S-1 80 mg m(-2) per day from day 1 to 14 every 3 weeks." | 5.17 | S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. ( Baek, JY; Jung, KH; K Shim, E; Kim, SY; Kong, SY; S Hong, Y; Shin, A, 2013) |
| "We conducted a phase I study of S-1 combined with irinotecan and oxaliplatin (TIROX) to determine the maximum-tolerated dose (MTD) and recommended dose (RD) and to assess its safety, pharmacokinetics, pharmacogenetics, and preliminary efficacy in patients with metastatic colorectal cancer (MCRC) or metastatic gastric cancer (MGC)." | 5.17 | Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. ( Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW, 2013) |
| "We have reported, in a randomized, controlled study, that tegafur-uracil(UFT)and protein-bound polysaccharide K(PSK)combination therapy significantly improves the 5-year disease-free survival rate and reduces the risk of recurrence compared to UFT alone for Stage II or III colorectal cancer." | 5.17 | [Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K]. ( Hirai, K; Kawate, S; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Toya, H; Yoshinari, D, 2013) |
| "This study attempted to determine the therapeutic dosage of irinotecan and S-1 (IRIS) as a second-line treatment for colorectal cancer (CRC)." | 5.17 | Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer. ( Akazawa, K; Funakoshi, K; Hasegawa, J; Hatakeyama, K; Maruyama, S; Okada, T; Takii, Y; Tani, T; Yamazaki, T, 2013) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer." | 5.17 | Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. ( Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K, 2013) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 5.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "Fluorouracil (5-FU) plus irinotecan combined with bevacizumab has significant activity in metastatic colorectal cancer (mCRC), but S-1 has become a substitute for continuous infusion of 5-FU and has a very low incidence of hand-foot syndrome." | 5.16 | Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Ichikawa, Y; Kato, K; Matsumoto, H; Shimada, Y; Yamada, Y; Yamaguchi, T, 2012) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 5.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "We investigated the efficacy and safety of the combination of irinotecan (CPT-11) and S-1 (IRIS regimen) as a first-line treatment in patients with metastatic colorectal cancer." | 5.16 | A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Ryoo, BY; Ryu, MH; Shin, JG, 2012) |
| "Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B)." | 5.16 | Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial. ( Hasegawa, H; Hisa, A; Kitagawa, Y; Ohishi, T; Okabayashi, K; Watanabe, M, 2012) |
| "The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer." | 5.16 | Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Yamada, Y, 2012) |
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 5.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| "Capecitabine plus oxaliplatin (CapeOX) is one of the reference doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer." | 5.16 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2012) |
| "To determine the efficacy and tolerance of irinotecan in combination with S-1 (IRIS) for patients whose disease progressed after treatment with an oxaliplatin-based therapy for colorectal cancer (CRC)." | 5.15 | Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. ( Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY, 2011) |
| "To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases." | 5.15 | Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011) |
| "To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer." | 5.15 | A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011) |
| "A combination of fluorouracil and leucovorin (5-FU/LV) with oxaliplatin (FOLFOX) is an established first-line therapy for metastatic colorectal cancer (mCRC)." | 5.15 | Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. ( Fujiwara, M; Iwata, N; Kodera, Y; Koike, M; Nakao, A; Nakayama, G; Ohashi, N; Okuda, N; Tanaka, C; Watanabe, T; Yokoyama, H, 2011) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 5.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "Three-drug combination of fluoropyrimidine, irinotecan and oxaliplatin has shown survival benefits in patients with metastatic colorectal cancer (mCRC)." | 5.14 | A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. ( Choi, HS; Hong, CW; Hong, YS; Jeong, SY; Jung, KH; Kim, BC; Kim, DY; Kim, SY; Park, JW; Sohn, DK, 2009) |
| "The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan (CPT-11) plus S-1 in advanced colorectal cancer." | 5.14 | A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K, 2009) |
| "Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest." | 5.14 | Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009) |
| "A 24-hour infusion of irinotecan combined with UFT/LV is feasible and active for metastatic colorectal cancer." | 5.14 | Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A, 2009) |
| "To determine the efficacy and tolerability of oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced colorectal cancer." | 5.14 | Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N, 2009) |
| "The combination of oral uracil/tegafur (UFT) plus leucovorin (LV) is widely accepted as adjuvant chemotherapy for stages II and III of colorectal cancer." | 5.14 | Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients. ( Furuhata, T; Hirata, K; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K, 2009) |
| "Both irinotecan (CPT-11) and S-1 are active against colorectal cancer; however, as S-1 is a prodrug of 5-fluorouracil (5-FU), 5-FU and its metabolites might inhibit the antitumour effect of CPT-11." | 5.14 | Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. ( Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Otsuka, K; Sakayori, N; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, S; Yoshioka, T, 2009) |
| " This phase I study was performed to determine the recommended dosage (RD) of metronomic chemotherapy using oral fluoropyrimidine S-1 plus weekly irinotecan (CPT-11) in patients with previously untreated advanced or recurrent colorectal cancer." | 5.14 | Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer. ( Akagi, Y; Ishibashi, N; Mori, S; Ogata, Y; Sasatomi, T; Shirouzu, K, 2009) |
| "We carried out this study to examine the health-related quality of life (HRQOL) of patients with advanced colorectal cancer treated with the oral fluoropyrimidine S-1 plus irinotecan (CPT-11)." | 5.14 | Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11). ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Tsunoda, Y; Watanabe, M; Yasuda, N, 2010) |
| "A combination of irinotecan with continuous infusional 5-fluorouracil (5-FU) is the standard treatment for advanced colorectal cancer." | 5.14 | A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Tsuchida, K; Yamamoto, N, 2010) |
| "Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer." | 5.14 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer." | 5.14 | Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. ( Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Futami, K; Kinugawa, N; Kusaba, H; Mibu, R; Mitsugi, K; Nakano, S; Sakai, K; Tanaka, R; Tanaka, S; Ueki, T, 2010) |
| "A randomized controlled trial was conducted to determine whether pathologic necrosis in response to preoperative treatment with uracil-tegafur(UFT) could be used to identify patients with colorectal cancer most likely to benefit from postoperative adjuvant therapy with the drug." | 5.13 | Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial. ( Fujii, M; Kochi, M; Takayama, T, 2008) |
| "Tegafur-uracil (UFT) plus leucovorin (LV, folinic acid) with alternating irinotecan and oxaliplatin were effective and well tolerated in patients with metastatic colorectal cancer (mCRC) in a phase I study." | 5.13 | Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Waddell, T; Wilson, G, 2008) |
| "Prolonged infusions have been shown to be safer and potentially more effective than bolus regimens of 5-fluorouracil (5-FU) as treatment for metastatic colorectal cancer (mCRC)." | 5.13 | A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. ( Abbruzzese, JL; Anthony, L; Hoff, PM; Kopetz, S; Langleben, A; Lassere, Y; Rinaldi, D; Thomas, MB; Wolff, RA, 2008) |
| "To evaluate the efficacy and safety of irinotecan combined with UFT for untreated and pretreated metastatic colorectal cancer." | 5.13 | Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S, 2008) |
| "This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease." | 5.12 | 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. ( Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006) |
| "Two phase III studies revealed an oral UFT/Leucovorin (LV) regimen, in which the drugs are taken for 28 consecutive days every 35 days, which proved to be equivalent to an infusional 5-fluorouracil/LV regimen for metastatic colorectal cancer (CRC)." | 5.12 | [Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer]. ( Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T, 2006) |
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 5.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| "This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens." | 5.12 | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. ( Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC, 2006) |
| "The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer." | 5.12 | Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G, 2007) |
| ") irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC)." | 5.12 | Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. ( Artru, P; Bennouna, J; Bugat, R; Delord, JP; Desseigne, F; Douillard, JY; Faroux, R; François, E; Husseini, F; Naman, H; Perrier, H; Piedbois, P; Smith, D, 2007) |
| "Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer." | 5.12 | A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ( Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007) |
| "Tissue samples from patients with pathologic ((p)) stage III colorectal cancer were tested for sensitivity to 5-fluorouracil (5-FU)." | 5.12 | An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. ( Isogai, A; Kubota, S; Matsuoka, H; Nagaya, M; Tsukikawa, S; Watanabe, T, 2007) |
| "To determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan plus S-1 in advanced colorectal cancer." | 5.12 | Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Nakao, K; Narita, K; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K; Yasuda, N, 2007) |
| "To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer." | 5.12 | Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. ( Beatty, PA; Benson, AB; Hochster, HS; Luo, W; Lyman, BT; Mulcahy, M; Popa, EC, 2007) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 5.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| " We investigated the benefits of oral protein-bound polysaccharide K (PSK) with tegafur/uracil (UFT) as an adjuvant in stage II and III colorectal cancer." | 5.11 | Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. ( Ikeya, T; Ishikawa, H; Iwazaki, S; Kakinuma, S; Kawate, S; Kusaba, T; Morishita, Y; Nakajima, T; Nakamura, S; Ohwada, S; Roppongi, T; Takahashi, T; Yokomori, T, 2004) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 5.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "To compare the efficacy, toxicities, and pharmacokinetics of an oral regimen consisting of uracil/tegafur (UFT) and leucovorin (LV) between Japanese patients and patients in the United States with previously untreated metastatic colorectal cancer." | 5.11 | Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. ( Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004) |
| "The purpose of this study was to evaluate the efficacy, assessed as response rate, and toxicity of UFT (Tegafur-Uracil) in combination with oxaliplatin as first-line treatment of advanced colorectal cancer (CRC)." | 5.11 | Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. ( Antón-Aparicio, L; Aparicio, J; Constela, M; Dorta, FJ; Feliu, J; Fonseca, E; García-Girón, C; Gonzalez-Baron, M; Lomas, M; Vicent, JM, 2004) |
| "Although intravenous (IV) 5-fluorouracil (5-FU) and uracil/futraful (UFT) have comparable antitumour efficacy in the treatment of metastatic colorectal cancer (MCC), we wanted to assess which of these two regimens would be preferred by our patients." | 5.11 | Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. ( del Giglio, A; Lima, AP, 2005) |
| " infusion; days 1, 8 and 15) combined with UFT (oral combination of tegafur and uracil) 200 mg/m2/day plus leucovorin (LV) 45 mg/m2/day (both divided into three separate oral doses every 8 h, days 1-21) every 4 weeks as first-line chemotherapy of metastatic colorectal cancer (CRC)." | 5.11 | Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. ( Alfonso, PG; Castañon, C; Cerezuela, P; Cruz, JJ; González, E; López-Mateos, Y; Méndez, M; Pujol, E, 2005) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 5.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "This randomised, open-label trial compared oral tegafur (FT)/leucovorin (LV) with the intravenous bolus 5-fluorouracil (5-FU)/LV as first-line chemotherapy for advanced colorectal cancer (CRC)." | 5.11 | Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. ( Arcusa, A; Batiste-Alentorn, E; Boleda, M; Campos, JM; Cirera, L; de Mendizábal, EV; de Olaguer, JP; Escudero, P; Galan, A; Guasch, I; Losa, F; Manzano, H; Méndez, M; Nogué, M; Saigí, E; Salud, A; Vicente, P, 2005) |
| "A phase II study was performed to evaluate the clinical efficacy and toxicity of oxaliplatin combined with uracil and tegafur (UFT) in patients with advanced colorectal cancer previously treated with a fluoropyrimidine-based regimen." | 5.10 | Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. ( Chun, H; Im, YH; Jung, CW; Kang, WK; Kim, JH; Kim, K; Kim, WS; Lee, HR; Lee, JY; Lee, MH; Lee, NS; Lee, WY; Nam, E; Oh, SY; Park, CH; Park, JO; Park, K; Park, SH; Song, SY, 2002) |
| "The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profile and response rate of the oral 5-fluorouracil prodrug UFT (tegafur/uracil) and leucovorin (LV) in combination with irinotecan in patients with advanced or metastatic colorectal cancer." | 5.10 | A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. ( Bailey, SM; Campbell, S; Cunningham, D; Glasspool, R; Hill, M; Macham, MA; Mackay, HJ; Martin, C; Massey, A; Price, T; Twelves, C; Uzzel, M, 2003) |
| "Adjuvant therapy using a combination of oral protein-bound polysaccharide K and tegafur/uracil is highly effective in preventing the recurrence of colorectal cancer in Stage II or III patients, and increases overall survival in pathological TNM Stage III." | 5.10 | Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. ( Ikeya, T; Kawashima, Y; Kawate, S; Kusaba, T; Morishita, Y; Nakajima, T; Nakamura, S; Ohwada, S; Roppongi, T; Takahashi, T; Yokomori, T, 2003) |
| ") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options." | 5.10 | Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002) |
| "The purpose of this study is to evaluate the efficacy of postoperative adjuvant chemotherapy using uracil and tegafur (UFT) for colorectal cancer." | 5.10 | Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. ( Baba, S; Hasumi, A; Kato, T; Koike, A; Manabe, T; Maruta, M; Miura, K; Nakazato, H; Nimura, Y; Ohashi, Y; Saji, S; Suzuki, H; Takagi, H; Yamaguchi, A, 2002) |
| "The objective of this study was to evaluate the activity and toxicity of tegafur and uracil (UFT; 1:4 molar ratio) plus leucovorin (LV) in patients with advanced colorectal cancer." | 5.09 | Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial. ( Antón-Torres, A; Aparicio, J; Aranda, E; Bretón, JJ; Carrato, A; Díaz-Rubio, E; Fernández-Martos, C; Navarro, M; Rivera, F; Sastre, J, 2001) |
| "This study was undertaken to address the influence of concurrent administration on the pharmacokinetics of UFT (uracil plus tegafur) and leucovorin (LV), and to measure the antitumor activity of a 28-consecutive-day oral regimen of UFT plus LV in patients with relapsed or refractory colorectal cancer." | 5.09 | Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. ( Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999) |
| "Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus or minus calcium folinate in elderly patients with advanced colorectal cancer." | 5.09 | UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Cervantes, A; Díáz-Rubio, E; Fernández Martos, C; Gallén, M; Marcuello, E; Massuti, T; Navarro, M; Rifá, J; Sastre, J, 1999) |
| "Oxaliplatin is a unique platinum compound with single-agent activity in both chemotherapy-naïve colorectal cancer patients and patients who progressed on 5-fluorouracil (5-FU)." | 5.09 | Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma. ( Hoff, PM; Pazdur, R, 1999) |
| "Data from a multinational phase III trial were analyzed to evaluate the use of in- and outpatient services for 373 patients with metastatic colorectal cancer being administered uracil/tegafur (in a molar ratio of 4:1 [UFT]) plus oral calcium folinate (Orzel) (N = 188) vs 5-fluorouracil (5-FU) plus oral calcium folinate (N = 185)." | 5.09 | Impact of uracil/tegafur plus oral calcium folinate on resource utilization. ( Ollendorf, D, 1999) |
| "This phase I trial combining UFT plus oral calcium folinate (Orzel) with irinotecan (CPT-11) (Camptosar) for the treatment of patients with advanced or metastatic colorectal cancer will open shortly." | 5.09 | UFT plus calcium folinate/irinotecan in colorectal cancer. ( Twelves, C, 1999) |
| "This study was designed to determine if histopathologic evaluation of patients with resectable colorectal cancer following preoperative chemotherapy with uracil and tegafur with a molar ratio of 4:1 (UFT) could predict chemosensitivity to postoperative fluoropyrimidines to prevent recurrence of disease." | 5.09 | Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer. ( Fujii, M, 1999) |
| "The aim of this study was to clarify whether increased 5-fluorouracil (5-FU) uptake by tumor tissue following preoperative UFT administration is a prognostic factor after surgery in colorectal cancer patients." | 5.09 | Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor. ( Ayabe, H; Eida, K; Furukawa, M; Ino, M; Ishikawa, H; Kunisaki, T; Nakagoe, T; Nakamura, Y; Nogawa, T; Sawai, T; Tobinaga, K; Tsuji, T, 2000) |
| "UFT (with leucovorin) and irinotecan both have single-agent activity in colorectal cancer, with non-cross-resistant mechanisms of action." | 5.09 | UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. ( Hill, M; Price, T, 2000) |
| "This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer." | 5.09 | UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer. ( Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G, 2000) |
| "In the United States and Europe, the combination of oral UFT plus leucovorin has been reported to produce objective responses and survival rates similar to those achieved with standard intravenous 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer, with reduced toxicity." | 5.09 | UFT plus leucovorin for metastatic colorectal cancer: Japanese experience. ( Ichikawa, W; Nihei, Z; Shirota, Y; Sugihara, K; Uetake, H; Yamada, H, 2000) |
| "The aim of the study was to investigate the possibility of dual modulation of UFT with leucovorin and hydroxyurea in a phase II trial of metastatic colorectal cancer." | 5.09 | Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer. ( Aabo, K; Hansen, F; Jakobsen, A; Pfeiffer, P; Sandberg, E, 2001) |
| " We wanted to determine whether the TS and DPD mRNA expression levels of gastric and colorectal cancer patients would be affected by tegafur (futrafur:FT)-based chemotherapy and whether changes in their expression might be responsible for patient outcome." | 5.09 | Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. ( Hayashi, K; Kuramochi, H; Takasaki, K; Uchida, K, 2001) |
| "Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer." | 5.09 | Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer. ( Arch-Yaemsuan, P; Boonnuch, W; Chakrapee-Sirisuk, S; Lert-Akayamanee, N; Lohsiriwat, D; Nimmanwudipong, T; Sinlarat, P; Srimuninnimit, V; Vathanophas, V, 2001) |
| "A combined phase I/II study (UFTM) of tegafururacil (UFT) and mitomycin C (MMC) was performed to find the optimal dosage for advanced colorectal cancer." | 5.08 | [Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer ( Ikeda, E; Isomoto, H; Kato, T; Kodaira, S; Okuda, M; Takahashi, T; Teramoto, T; Yamamoto, Y, 1996) |
| "The activity and toxicity of UFT (Tegafur and Uracil) in a 4:1 molar concentration, plus leucovorin (LV), were evaluated in the treatment of 45 patients with advanced, bidimensionally measurable metastatic colorectal carcinoma." | 5.08 | Phase II study of UFT plus leucovorin in colorectal cancer. ( Pazdur, R, 1997) |
| "A phase II trial of UFT (Tegafur and Uracil) modulated by leucovorin was undertaken by the Oncopaz Cooperative Group to assess the efficacy and toxicity of this combination in patients with advanced colorectal cancer." | 5.08 | UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. ( Blanco, E; Colmenarejo, A; Crespo, MC; de Castro, J; Espinosa, E; Espinosa, J; Feliu, J; Garcia Girón, C; González Barón, M; Juárez, F; Martinez, B; Ordóñez, A, 1997) |
| "Therapeutic options for patients with advanced colorectal cancer who have failed treatment with fluorouracil (5-FU) are limited." | 5.08 | Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. ( Birkhofer, MJ; Meropol, NJ; Noel, D; Sonnichsen, DS, 1997) |
| "The results of this study show that an all-oral regimen of tegafur and leucovorin can obtain biochemical modulation, with a significant response rate, in patients with advanced colorectal carcinoma." | 5.08 | Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. ( Antón, I; Arcusa, A; Batiste-Alentorn, E; Boleda, M; Nogué, M; Saigí, E; Seguí, MA, 1998) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "5-Fluorouracil (5-FU) has been the most widely used chemotherapeutic agent for metastatic colorectal cancer (mCRC) and 5-FU combination therapy improves efficacy compared with monotherapy." | 4.85 | The role of UFT in metastatic colorectal cancer. ( Bennouna, J; Douillard, JY; Saunders, M, 2009) |
| "In Western countries, efficacy of 5-fluorouracil (5-FU)+leucovorin (LV) as adjuvant chemotherapy for colorectal cancer has been already established." | 4.83 | [Adjuvant chemotherapy for colorectal cancer]. ( Akasu, T, 2006) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 4.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| "A combination therapy of irinotecan hydrochloride (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is often used to treat advanced colorectal cancer." | 4.83 | [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. ( Goto, A, 2006) |
| "Since its synthesis over 40 years ago, several studies including patients with colorectal cancer have shown that prolonged exposure to 5-fluorouracil (5-FU) is associated with better antitumor activity and decreased toxicity." | 4.82 | Practical considerations in the use of oral fluoropyrimidines. ( Hoff, PM, 2003) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 4.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| "5-fluorouracil (5-FU) plus leucovorin (LV) therapy is the most widely used regimen with a high evidence as the first-line treatment for advanced colorectal cancer (CRC), as well as CPT-11 as the second-line." | 4.82 | [Chemotherapy for colorectal carcinoma]. ( Enomoto, M; Higuchi, T; Sugihara, K; Uetake, H, 2003) |
| " Oral prodrugs of 5-FU, such as capecitabine and uracil, have been developed in order to mimic the protracted infusion schedule of 5-FU, and these drugs may change the daily practice of palliative chemotherapy for colorectal cancer in the coming years." | 4.82 | New developments in systemic chemotherapy in advanced colorectal cancer. ( Cats, A, 2003) |
| "5-Fluorouracil (5-FU) administered in several schedules since its introduction in 1957 continues to be an integral part of standard first-line therapy for colorectal cancer." | 4.82 | The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. ( Beretta, GD; Labianca, R; Milesi, L; Mosconi, S, 2004) |
| "5-Fluorouracil (5-FU) has been utilized as part of standard chemotherapy for treatment of early-stage and metastatic colorectal cancer for more than 4 decades." | 4.81 | Oral fluoropyrimidine treatment of colorectal cancer. ( Eng, C; Kindler, HL; Schilsky, RL, 2001) |
| "In colorectal cancer, leucovorin-modulated 5-fluorouracil (5-FU) has been the mainstay of both adjuvant treatment and treatment of metastatic disease for many years." | 4.81 | Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. ( Cunningham, D; James, RD, 2001) |
| "For several decades fluoropyrimidines, especially 5-fluorouracil (5-FU), have played a role in standard chemotherapy regimens for a range of solid tumours, including breast and colorectal cancers." | 4.81 | New options for outpatient chemotherapy--the role of oral fluoropyrimidines. ( Coleman, R; Cunningham, D, 2001) |
| "5-Fluorouracil (5-FU) has been the mainstay of systemic therapy for colorectal cancer since its initial development 40 years ago." | 4.80 | Oral fluoropyrimidines in the treatment of colorectal cancer. ( Meropol, NJ, 1998) |
| "After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer." | 4.80 | Fluoropyrimidines: a critical evaluation. ( Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH, 1999) |
| "For years, 5-fluorouracil (5-FU) was the only chemotherapeutic agent for the treatment of patients with advanced colorectal cancer." | 4.80 | New drugs in therapy of colorectal cancer: preclinical studies. ( Cao, S; Rustum, YM, 1999) |
| "Protracted intravenous infusions of fluorouracil (5-FU) in the treatment of colorectal cancer have been associated with a reduction in toxicity and enhanced clinical activity compared with bolus 5-FU schedules." | 4.80 | Oral fluoropoyrimidines. ( Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M, 1999) |
| " This review describes several oral fluoropyrimidine regimens with activity in colorectal cancer: capecitabine (Xeloda), tegafur, UFT, S-1, and eniluracil plus 5-FU." | 4.80 | Oral therapy for colorectal cancer: how to choose. ( Damjanov, N; Meropol, NJ, 2000) |
| "Fluorouracil has been the mainstay of treatment for colorectal cancer (CRC) for almost 40 years." | 4.80 | Progress in colorectal cancer chemotherapy: how far have we come, how far to go? ( Hoff, PM; Pazdur, R; Royce, ME, 2000) |
| "For several years, fluorinated pyrimidines have been used in the treatment of advanced colorectal cancer, mainly in the form of intravenous injections of 5-fluorouracil (5-FU), alone or in combination with leucovorin." | 4.80 | [Fluorinated pyrimidines in oral treatment of advanced colorectal cancer]. ( Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L, 2000) |
| "Fluorouracil (5-FU) has remained the standard therapy for the treatment of advanced colorectal cancer for over 40 years." | 4.80 | Colorectal cancer: chemotherapy treatment overview. ( Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH, 2000) |
| "We evaluated the pharmacokinetics and pharmacodynamics/toxicodynamics of uracil-tegafur (UFT) after multiple administrations in colorectal cancer (CRC) model rats, and applied a pharmacometric approach to describe the time-course alterations of plasma 5-FU concentrations and tumor shrinkage." | 4.31 | A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model. ( Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023) |
| "This study suggests that tegafur/uracil plus leucovorin is a feasible adjuvant chemotherapy regimen for patients with stage II colorectal cancer after curative surgical treatment." | 4.31 | Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan. ( Chen, HH; Fan, CW; Liao, CK; Liaw, YW; Liu, YH; Tseng, WK; Yeh, CY; Yu, YL, 2023) |
| "Combination therapy of tegafur/uracil (UFT) and leucovorin (LV) is widely used to treat colorectal cancers." | 4.02 | Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy. ( Endo, Y; Hirashita, T; Inomata, M; Itoh, H; Iwao, M; Iwashita, Y; Masuda, T; Shiraiwa, K; Suzuki, Y; Tada, K; Tanaka, R; Uchida, H, 2021) |
| "Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer." | 3.91 | Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. ( Hsu, TC; Wang, CC, 2019) |
| "Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy." | 3.85 | Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017) |
| "This study sought to compare UFT/LV with capecitabine as adjuvant chemotherapy for the treatment of stage III colorectal cancer." | 3.83 | [Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer]. ( Maruyama, T; Okumura, M; Sako, A; Ueda, K; Yasuda, K, 2016) |
| "S-1, an oral 5-fluorouracil (5-FU)-based medicine that combines tegafur, gimeracil and oteracil potassium is commonly used as an adjuvant chemotherapeutic drug for the treatment of colorectal cancer." | 3.83 | Prediction of Early Recurrence After Curative Resection of Colorectal Liver Metastasis and Subsequent S-1 Chemotherapy. ( Kokuryo, T; Nagino, M; Uehara, K; Yamaguchi, J; Yamauchi, K; Yokoyama, Y, 2016) |
| "To analyze the therapeutic actions of tegafur gimeracil oteracil combined with oxaliplatin for treating patients with advanced colorectal cancer, and its effects on the K-ras gene mutation and the CK20 mRNA." | 3.81 | Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer. ( Ren, J; Wei, H; Yang, ZH; Yi, LJ; Zheng, JH, 2015) |
| "5-Fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) therapy and 5-FU, leucovorin, and irinotecan (FOLFIRI) therapy are standard chemotherapies to treat advanced/recurrent colorectal cancer." | 3.80 | Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer. ( Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014) |
| "The effectiveness of 5-fluorouracil (5-FU)-based adjuvant chemotherapy is reported in patients with colorectal cancer (CRC), but the usefulness of 5-FU metabolic enzymes as predictive biomarkers of the efficacy of this chemotherapy remains unclear." | 3.80 | Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. ( Hasegawa, H; Ishii, Y; Kitagawa, Y; Okabayashi, K; Shigeta, K, 2014) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 3.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "To identify useful predictive factors for the response to 5-fluorouracil (5-FU)/leucovorin (LV) and oral uracil and tegafur (UFT)/LV chemotherapy among patients with colorectal cancer, we investigated the association between the gene expression levels of pyrimidine and folate metabolism-related enzymes in colorectal cancer (CRC) tissues and the response to UFT/LV neoadjuvant chemotherapy." | 3.78 | Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. ( Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2012) |
| "Oxaliplatin is effective when used with 5-fluorouracil (5-FU) and leucovorin, or with capecitabine (COX) for the treatment of colorectal cancer." | 3.78 | Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo. ( Kobunai, T; Nakagawa, F; Nukatsuka, M; Saito, H; Sakamoto, K; Shiraishi, K; Takechi, T; Uchida, J, 2012) |
| "The purpose of the study was to evaluate the efficacy and tolerability of S-1 monotherapy in metastatic colorectal cancer (CRC) patients who have failed the standard oxaliplatin-based or irinotecan-based chemotherapy." | 3.77 | Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy. ( Kang, WK; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, SY, 2011) |
| "Injectable combination chemotherapy with 5-fluorouracil (5-FU)/Leucovorin (LV), oxaliplatin (OHP), and irinotecan (CPT-11) has been a standard treatment for advanced colorectal cancer (CRC)." | 3.77 | [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer]. ( Matsueda, S; Sasaki, H; Tokunaga, Y, 2011) |
| "Overall health-related quality of life did not deteriorate during adjuvant chemotherapy with oral uracil/tegafur plus leucovorin in patients with colorectal cancer, despite the effect from surgical damage, whereas the development of Grade 3 toxicities negatively affected on short-term health-related quality of life." | 3.76 | Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| "Quality of life (QOL) was measured prospectively using the European Organization for Research and Treatment of Cancer QLQ-C30 (QLQ-C30) and Functional Assessment of Cancer Therapy-General (FACT-G) in 94 colorectal cancer patients who received adjuvant chemotherapy with oral uracil/tegafur plus leucovorin." | 3.76 | [European Organization for Research and Treatment of Cancer QLQ-C30 and functional assessment of cancer therapy- general for measurement of quality of life in colorectal cancer patients who received adjuvant chemotherapy- a comparison]. ( Tsunoda, A, 2010) |
| "To establish the sufficient therapy for elderly colorectal cancer patients, we retrospectively compared postoperative Tegafur/Uracil (UFT; Taiho Pharmaceutical Co." | 3.75 | Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. ( Takashima, S; Yoshitani, S, 2009) |
| "Chemotherapy with irinotecan (CPT-11) or oxaliplatin (l-OHP) in combination with infusional 5-fluorouracil (5-FU) and their cross-over as second-line therapies are standard treatments for metastatic colorectal cancer (MCRC)." | 3.75 | Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. ( Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2009) |
| " This study was conducted to examine changes in DPD activity in peripheral mononuclear cells (PMNC) during long-term treatment with oral uracil and tegafur (UFT) for colorectal cancer." | 3.74 | Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. ( Ishikawa, K; Kamijo, A; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, Y; Yasuda, S, 2007) |
| "We report two cases of recurrent colorectal cancer in two patients who were treated successfully with a combined oral chemotherapeutic agent folinate/tegafur/uracil (UFT/LV) dosage." | 3.74 | [Two cases of recurrent colorectal cancer treated successfully with folinate/tegafur/uracil (UFT/LV) chemotherapy on an outpatient basis]. ( Hosotaki, K; Shimamoto, M; Tabira, Y; Tamori, Y, 2008) |
| "To evaluate ambulatory patient cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 19 patients with non-curative or recurrent colorectal cancer who were treated by Uracil/Tegafur (UFT) plus oral Leucovorin (UZEL) for the past 2 years." | 3.73 | [Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer]. ( Fujiwara, H; Hamabe, Y; Ishida, T; Kaji, M; Mukai, H; Mukubou, H; Onishi, N; Sato, S; Toyokawa, A; Tsujimura, T; Tsukamoto, T; Wakahara, T; Wakita, K; Watanabe, A, 2005) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 3.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| "Concomitant treatment with 5-fluorouracil (5-FU) and Leucovorin (LV) is positioned as the standard chemotherapy against colorectal cancer." | 3.72 | [Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer]. ( Anazawa, S; Hirai, K; Kawahara, H; Ogawa, M; Sakuyama, T; Sato, K; Takao, Y; Yamazaki, Y; Yokoyama, M, 2004) |
| "The purpose of this study was to examine the relation between tumoral expression of dihydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of the degradation pathway 5-fluorouracil (5-FU), and the efficacy of 5-FU based chemotherapy for colorectal cancer." | 3.72 | [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. ( Hashimoto, D; Inokuma, S; Ishida, H; Nakada, H; Ohsawa, T; Shirakawa, K; Yamada, H; Yokoyama, M, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 3.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "(1) The standard chemotherapy for metastatic colorectal cancer is intravenous fluorouracil combined with calcium folinate." | 3.71 | Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages. ( , 2002) |
| "In an effort to improve the therapeutic selectivity of 5-fluorouracil (FUra) against colorectal cancer, S-1, a combination agent including a prodrug of FUra with two modulators, was recently developed by Taiho Pharmaceuticals Co." | 3.70 | Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. ( Cao, S; Lu, K; Rustum, YM; Shirasaka, T; Slocum, HK; Tóth, K, 1999) |
| " A high incidence of colorectal adenocarcinomas with varied grades of cell differentiation can be induced by 1,2-dimethylhydrazine (DMH) in rats." | 3.69 | Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats. ( Iwama, T; Kawachi, Y; Kudo, H; Murakami, S; Okayasu, I; Sagara, T; Sakamoto, S; Tsukada, K, 1997) |
| "In order to elucidate the effect of tumor vascularity on a various regimens concentration in tumor tissue, correlation among tegafur, 5-fluorouracil (5-FU), uracil concentrations in tissue and the microangiography were examined in 27 patients with colorectal cancer after preoperative administration of UFT (400 mg/day for 7 days)." | 3.68 | [Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer]. ( Ishikawa, H; Kusano, H; Miyashita, K; Nakazaki, T; Ogawa, T; Shimizu, T; Shimoyama, T; Yasutake, T; Yoshida, A; Yoshida, K, 1993) |
| " UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer." | 3.68 | [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992) |
| "A phase II trial of continuous oral therapy with UFT, a combination of uracil and the 5-fluorouracil analogue 1-(2-tetrahydrofuryl)-5-fluorouracil (Futraful, Ftorafur), was conducted in 40 patients with advanced colorectal cancer and 18 patients with advanced gastric cancer." | 3.68 | Phase II trial of UFT in advanced colorectal and gastric cancer. ( Clarke, PI; Malik, ST; Osborne, R; Reznek, R; Slevin, ML; Talbot, D; Wrigley, PF, 1990) |
| "5-fluorouracil (5-FU) concentrations in peripheral blood, portal blood, normal and cancer tissues were evaluated in 26 patients with colorectal cancer after SF-SP administration (800 mg/day for 10 days)." | 3.68 | [Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration]. ( Haruyama, K; Hase, S; Ishizawa, T; Katsura, Y; Niwa, K; Sameshima, T; Shimazu, H; Yamada, K; Yoshimura, A, 1990) |
| "The concentration of Tegafur, 5-FU and Uracil in tumor and normal tissue were measured in 47 colorectal cancer patients who had been administered UFT (400/mg) for seven days before operation." | 3.67 | [Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration]. ( Eida, K; Fukuda, Y; Hirano, T; Ishii, T; Kotake, Y; Kusano, H; Nakagoe, T; Shimizu, T; Shimoyama, T; Tomita, M, 1988) |
| "Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated." | 3.01 | Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). ( Doki, Y; Eguchi, H; Haraguchi, N; Ide, Y; Kim, H; Kudo, T; Matsuda, C; Mizushima, T; Murata, K; Nakata, K; Nishizawa, Y; Okamura, S; Satoh, T; Uemura, M, 2021) |
| " We designed the study of XSLJZD combined with S-1 in the maintenance therapy of Stage III or IV GC and CRC, and hoped that this research program will go further and comprehensively evaluate its efficacy and safety." | 2.94 | Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma. ( Hong, XC; Hu, KH; Liang, QL; Luo, XB; Ou, WT; Yang, HX; Zhang, HJ, 2020) |
| "The treatment of refractory metastatic colorectal cancer (rmCRC) and the lack of predictive variables are matters of debate." | 2.87 | MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression. ( Alabiso, I; Alabiso, O; Baratelli, C; Brizzi, MP; Di Maio, M; Forti, L; Ottone, A; Scagliotti, GV; Sonetto, C; Tampellini, M, 2018) |
| " The overall incidence of any Grade adverse events (AEs) were 91." | 2.87 | Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. ( Aiba, K; Baba, H; Boku, N; Ishiguro, M; Itabashi, M; Kotake, K; Kunieda, K; Kusumoto, T; Maeda, A; Mochizuki, I; Morita, S; Okabe, M; Ota, M; Sakamoto, Y; Sugihara, K; Sunami, E; Takahashi, K; Tomita, N; Yamauchi, J; Yoshida, K, 2018) |
| " In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with bevacizumab for a similar population are reported." | 2.82 | Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU ( Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016) |
| "Irinotecan (125 mg/m(2)) was administered as a 24-hour infusion on days 1 and 15, S-1 (80 mg/m(2)) was administered orally on days 1-14, and bevacizumab (5." | 2.80 | A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ( Kamijo, A; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A, 2015) |
| " The goal of this trial was to evaluate the efficacy of TSU-68 in combination with SOX." | 2.79 | A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. ( Choi, YJ; Chun, HG; Chung, HC; Chung, IJ; Han, SW; Kim, JG; Kim, SY; Kim, TW; Kim, YH; Lee, J; Shin, DB; Shin, SJ; Song, HS, 2014) |
| "8% and grade 3 or higher adverse events occurred in 12." | 2.79 | A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study. ( Hasegawa, K; Ijichi, M; Kawasaki, S; Kokudo, N; Koyama, H; Makuuchi, M; Miyagawa, S; Oba, M; Saiura, A; Takayama, T; Teruya, M; Yamamoto, J; Yoshimi, F, 2014) |
| "We conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer." | 2.78 | [Treatment outcome of peptide vaccination for advanced colorectal cancer]. ( Hida, J; Inoue, K; Kogita, A; Okuno, K; Sugiura, F; Sukegawa, Y; Yoshioka, Y, 2013) |
| " We conducted a phase I study to evaluate the safety and pharmacokinetic of TSU-68 when used with S-1 and oxaliplatin (SOX) in metastatic colorectal cancer (mCRC) patients." | 2.77 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. ( Ahn, JB; Chung, HC; Jeung, HC; Jung, M; Kim, HR; Rha, SY; Roh, JK; Shin, SJ, 2012) |
| "The response rate of S-1 for colorectal cancer is high, ranging from 35% to 40%." | 2.75 | Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. ( Boku, N; Furuhata, T; Hyodo, I; Kato, T; Koizumi, W; Miyashita, K; Miyata, Y; Nishina, T; Okada, Y; Sawaki, A; Toh, Y; Yamaguchi, K, 2010) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 2.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "Patients with advanced or metastatic colorectal cancer (CRC) received: UFT 300 mg/m(2), LV 75 mg/body and CPT-11 150 mg/m(2) (UFT and LV given on days 1-14, and CPT-11 on day 1, every 3 weeks)." | 2.74 | A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. ( Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y, 2009) |
| "S-1 showed clinical activity in colorectal cancer, and the preclinical data of S-1 with oxaliplatin showed synergistic activity in an animal model." | 2.74 | A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer. ( Kang, EM; Kang, WK; Kim, HS; Lee, HY; Lee, J; Lee, Y; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE, 2009) |
| " In this single-dose, randomized, two-way crossover study, we investigated the effects of a low-fat Japanese meal on the pharmacokinetics and oral bioavailability of UFT (2 x 100-mg capsules; dose in terms of tegafur) and leucovorin (1 x 25-mg tablet)." | 2.74 | Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer. ( Furuhata, T; Hosokawa, Y; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K; Sasaki, K; Tsuruma, T, 2009) |
| "The purpose of this study was to determine the optimal dose of oxaliplatin, when combined with a fixed dose of S-1 (40 mg/m twice daily on days 1-14) on a 3-week schedule, for patients with advanced and/or metastatic colorectal cancer." | 2.73 | Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer. ( Cao, J; Li, J; Liu, Y; Lu, F; Yin, J; Zhu, X; Zuo, Y, 2008) |
| "This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX)." | 2.73 | Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. ( Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N, 2007) |
| "Twenty-two patients with metastatic colorectal cancer were enrolled in the phase I trial and 35 patients (including eight patients treated at level 4 during phase I) were evaluated in the phase II trial." | 2.73 | Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102. ( Fukunaga, M; Furukawa, H; Gotoh, M; Ishida, H; Ishihara, R; Narahara, H; Okamura, S; Takiuchi, H; Tomita, N; Uedo, N, 2007) |
| "Although the prognosis in patients with pancreatic cancer has been poor, we recently reported unusually high response rate and survival benefit of S-1 treatment in patients with pancreatic cancer." | 2.73 | High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. ( Danenberg, KD; Danenberg, PV; Hatori, T; Hayashi, K; Kuramochi, H; Nakajima, G; Uchida, K; Yamamoto, M, 2008) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 2.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "In total 47 patients with colorectal cancer were included." | 2.71 | EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. ( de Boer, RF; Duffaud, F; Fumoleau, P; Reinke, F; Roth, AD; Schellens, JH; Schöffski, P; Van den Brande, J; Vermorken, JB; Wanders, J; Weigang-Köhler, K, 2003) |
| "In addition, remote metastases tended to be suppressed for both colon and rectal cancer in Group A (p=0." | 2.71 | Pre- and post-operative adjuvant chemotherapy in colorectal cancer. ( Isomoto, H; Kakegawa, T; Mori, M; Nakagoe, T; Ogawa, M; Sugimachi, K; Takano, S; Tomita, M; Yamada, K, 2003) |
| " The pharmacokinetic profiles of the tegafur, CDHP, and oxonic acid constituents were characterized." | 2.71 | Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. ( Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G, 2004) |
| "Patients with advanced (stage IV) colorectal cancer were treated with S-1 twice daily based on the patient's body surface area (BSA; BSA < 1." | 2.71 | Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. ( Danenberg, KD; Danenberg, PV; Hayashi, K; Kuramochi, H; Schneider, S; Takasaki, K; Uchida, K; Yang, D; Yochim, JM, 2005) |
| "Colorectal cancer is usually diagnosed in elderly patients." | 2.71 | Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. ( Blanco, G; Bordonaro, R; Cordio, S; Manzione, L; Reggiardo, G; Rosati, G; Tucci, A, 2005) |
| " The effect of food on the oral bioavailability of UFT (2 x 100 mg capsules; dose in terms of FT) and leucovorin (2 x 15 mg tablets) was evaluated in a single-dose, randomized, two-way crossover study." | 2.70 | Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. ( Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 2.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| " Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128." | 2.69 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. ( Aiba, K; Denno, R; Hirata, K; Horikoshi, N; Ishizuka, H; Nakano, Y; Okazaki, M; Sasaki, K; Shirasaka, T; Taguchi, T; Uno, S; Yamada, Y, 1999) |
| "Twenty-two colorectal cancer patients (infusion group) in Dukes' C stage were given hepatic arterial infusion of 5-FU (500 mg/body for 1 hr per week, repeated 50 times) and peroral UFT-E (2." | 2.69 | [Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer]. ( Fujioka, M; Idezuki, Y; Inokuma, S; Ishida, H; Kamano, T; Kishi, T; Kondo, K; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Shimomura, K; Suzuki, T; Takeuchi, I; Yamada, H, 1999) |
| " Four patients who suffered from PMC-related side effects of grade 1-2 wanted to decrease their dosage of UFT and/or 5-FU." | 2.69 | [Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report]. ( Izumi, S; Nakagawa, J; Nishihara, M; Onoda, Y; Shimizu, N; Shiota, K; Suzuka, I, 1999) |
| "Twenty cases of advanced colorectal cancer were entered into the study." | 2.69 | Efficacy of UFT plus oral leucovorin in advanced colorectal cancer: a multicenter study. ( Laohavinij, S; Maoleekoonpairoj, S; Thavichaigarn, P; Thongprasert, S, 2000) |
| "Pharmacokinetic modulating chemotherapy (PMC) is a new therapeutic concept in combination with continuous 5-fluorouracil (5-FU) infusion and UFT." | 2.69 | Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2000) |
| " We describe the design of a phase II study to investigate the safety and efficacy of UFT/leucovorin combined with mitomycin-C in a larger group of previously untreated patients with metastatic colorectal cancer." | 2.69 | UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca. ( Jakobsen, A, 2000) |
| "79 patients with measurable advanced colorectal cancer (CRC) and no prior chemotherapy were included." | 2.68 | Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. ( Blanco, E; Colmenarejo, A; de la Gándara, I; Espinosa, E; Feliu, J; García-Girón, C; Garrido, P; González-Barón, M; Juárez, F; Martínez-Martínez, B, 1995) |
| "The subjects were 39 patients with gastric cancer and 44 patients with colorectal cancer divided into a group administered 400 mg/day of UFT orally for 2 weeks preoperatively (UFT group) and a group administered 400 mg/day of UFT as well as 40 mg/m2 (i." | 2.68 | [Study of preoperative combination therapy with UFT + CDDP in patients with gastric and colorectal cancer--concomitant effects based on the thymidylate synthase inhibitory rat]. ( Fuchino, Y; Ikeda, S; Kimura, H; Mitsuishi, K; Tanaka, S; Tomita, A; Umeno, T, 1997) |
| " Odds ratio and hazard ratio of available outcomes including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were pooled for analysis." | 2.61 | Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis. ( Chen, J; Wang, J; Xu, T, 2019) |
| "Treatment with eniluracil with oral 5-FU was associated with inferior PFS and OS among participants treated with palliative intent for CRC, and eniluracil is no longer being developed." | 2.55 | Oral versus intravenous fluoropyrimidines for colorectal cancer. ( Chionh, F; Lau, D; Price, T; Tebbutt, N; Yeung, Y, 2017) |
| "This review aims to provide an evidence-based update of clinical trials that have investigated the clinical efficacy, adverse-event profile, dosage and administration of S-1, given alone or in combination with conventional chemotherapeutics and new target-oriented drugs, in the management of colorectal cancer (CRC)." | 2.50 | Efficacy of S-1 in colorectal cancer. ( Baba, H; Miyamoto, Y; Sakamoto, Y; Yoshida, N, 2014) |
| "Chemotherapy for advanced colorectal cancer is much improved in this decade." | 2.43 | [Second-line chemotherapy for advanced colorectal cancer]. ( Enomoto, M; Higuchi, T; Iida, S; Sugihara, K; Tsunozaki, H; Uetake, H; Yasuno, M, 2005) |
| "Case 1 of type 3 advanced gastric cancer underwent surgery after one week interval following oral administration of TS-1 at a daily dose of 80 mg/body for 2 weeks." | 2.43 | [Evaluation of pre-operative administration of TS-1 in patients with advanced gastric or colorectal cancer--estimation of pathological effectiveness for postoperative adjuvant chemotherapy with TS-1]. ( Koizumi, H; Nakamura, K; Nakane, Y; Nakano, K; Okugawa, K; Osaka, Y; Sako, H; Tanabe, S; Tsuchiya, K, 2005) |
| "A patient with metastatic colorectal cancer should today be expected to have a median survival of 18-20 months compared to that of 11-14 months only a few years ago." | 2.43 | Chemotherapy for colorectal cancer. ( Goyle, S; Maraveyas, A, 2005) |
| "In stage II colon cancer, treatment strategies are more debated." | 2.43 | [Adjuvant treatment of colorectal cancer]. ( Afchain, P; André, T; de Gramont, A; Segura, C, 2006) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| "Metastatic colorectal cancer has a poor prognosis, and the majority of patients are left with palliative measures." | 2.42 | Palliative treatment of patients with colorectal cancer. ( Glimelius, B, 2003) |
| "New targets in the treatment of colorectal cancer are the EGF and VEGF receptor." | 2.42 | The role of new agents in the treatment of colorectal cancer. ( Folprecht, G; Köhne, CH, 2004) |
| "Adjuvant radiation therapy for rectal cancer is not widely used in Japan, while chemotherapy is considered the adjuvant treatment of choice." | 2.41 | [Progress in adjuvant therapy for colorectal cancer]. ( Kakeji, Y; Kohnoe, S; Maehara, Y, 2002) |
| "Among colorectal cancer patients with recurrent or metastatic sites, survival was significantly prolonged for a group undergoing LV/5-FU therapy based on biochemical modulation compared with a group receiving no chemotherapy (best supportive care)." | 2.41 | [Progress in chemotherapy for colorectal cancer]. ( Maeda, Y; Sasaki, T, 2000) |
| "Treatment for advanced colorectal cancer has nevertheless made progress in the last few years." | 2.41 | New drugs and combinations in the palliative treatment of colon and rectal cancer. ( Beretta, GD; Labianca, R; Mosconi, S; Pessi, MA; Poletti, P, 2001) |
| "Metastatic colorectal cancer has traditionally been treated with i." | 2.41 | Answering patients' needs: oral alternatives to intravenous therapy. ( Borner, M; Maroun, J; Scheithauer, W; Twelves, C; Wilke, H, 2001) |
| "Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment." | 2.41 | New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. ( Holen, KD; Saltz, LB, 2001) |
| "The review focuses on the treatment of colorectal cancer and summarizes the Japanese experience and the phase I and II trials performed in the United States and Europe." | 2.40 | Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. ( Benner, SE; Canetta, RM; Sulkes, A, 1998) |
| "Tegafur acts as a prodrug of 5-fluorouracil (5-FU), being slowly metabolized by cytochrome P450 to 5-FU." | 2.40 | UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ( Benner, SE; Canetta, R; Hoff, PM; Pazdur, R, 1998) |
| "5-fluorouracil has been the major chemotherapeutic agent for the treatment of colorectal carcinoma for the past four decades." | 2.40 | A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. ( Adjei, AA, 1999) |
| "Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours." | 2.40 | Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. ( Hoff, PM; Lassere, Y; Pazdur, R, 1999) |
| "It revealed a peritoneal recurrence in the pouch of Douglas." | 1.72 | [A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection]. ( Arakawa, A; Ii, Y; Irie, T; Kawaguchi, M; Kawai, M; Kobari, A; Kojima, Y; Momose, H; Sakamoto, K; Sugimoto, K; Terao, Y; Tomiki, Y; Tsukamoto, R, 2022) |
| "Stage II colorectal cancer has a relatively good prognosis." | 1.62 | Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer. ( Chen, TC; Jeng, YM; Liang, JT, 2021) |
| "At the age of 78 advanced colorectal cancer (stage IIIa) was diagnosed and laparoscopic-assisted colectomy was performed." | 1.56 | Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report. ( Fujii, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Imafuku, A; Kawada, M; Mizuno, H; Ohashi, K; Sawa, N; Sekine, A; Suwabe, T; Toriu, N; Ubara, Y; Yamanouchi, M, 2020) |
| " Clinically, metronomic S-1 dosing has been approved for the standard first- and second-line treatment of metastatic or advanced stage of colorectal (CRC)." | 1.46 | Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model. ( Abu Lila, AS; Fukushima, M; Huang, CL; Ishida, T; Moriyoshi, N; Wada, H, 2017) |
| "We recently reported that combination therapy with metronomic S-1 dosing and oxaliplatin (l-OHP)-containing PEGylated liposomes improved antitumor activity in a murine colorectal tumor model." | 1.40 | Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome. ( Abu Lila, AS; Doi, Y; Ishida, T; Kiwada, H; Nagao, A; Nakamura, H, 2014) |
| "Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy." | 1.40 | Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014) |
| " The baseline characteristics, progressive-free survival, overall survival time and adverse events were retrospectively analyzed." | 1.40 | [Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses]. ( Guo, Z; Hong, L; Li, B; Liu, C; Si, T; Yu, H, 2014) |
| "The dosing regimen for 1 course was as follows: BV (7." | 1.40 | [Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer]. ( Higashi, Y; Ishikawa, S; Maruo, H; Murakami, T; Nishiyama, R; Shoji, T; Suzuki, K; Taniguchi, M; Yamazaki, M, 2014) |
| " Two patients received only SOX as chemotherapy, while the others received SOX in combination with one of the three molecular-targeting agents, bevacizumab, cetuximab, and panitumumab." | 1.39 | Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "98 gastric and 135 colorectal cancer patients were analyzed." | 1.39 | Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK). ( Ikeda, T; Ikegami, T; Kawanaka, H; Maehara, Y; Mimori, K; Morita, M; Oki, E; Saeki, H; Soejima, Y; Sugimachi, K; Uchiyama, H; Watanabe, M; Yamashita, Y; Yoshinaga, K; Yoshizumi, T, 2013) |
| "We recently proposed an S-1 combined with oxaliplatin (SOXL) regimen, a combination treatment consisting of oral metronomic S-1 dosing and intravenous administration of oxaliplatin (l-OHP) containing PEGylated liposomes, which showed potent antitumor activity in vivo." | 1.39 | Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application. ( Abu Lila, AS; Ishida, T; Kiwada, H; Nagao, A, 2013) |
| " Recently, we showed that the combination of oral metronomic S-1 dosing with oxaliplatin (l-OHP)-containing PEG-coated "neutral" liposomes exerted excellent antitumor activity." | 1.38 | Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism? ( Abu Lila, AS; Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Okada, T, 2012) |
| " Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events." | 1.37 | Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. ( Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S, 2011) |
| "The aim of this study is to identify colorectal cancer specific gene methylation determining chemosensitivity to S-1/CPT-11 therapy." | 1.36 | CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients. ( Hashiguchi, K; Hiraki, M; Kitajima, Y; Miyazaki, K; Nakafusa, Y; Nakamura, J; Noshiro, H; Sumi, K, 2010) |
| "HRQOL in colorectal cancer patients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased stage of tumor between the groups." | 1.36 | Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| " However, many patients are often forced to give up long-term S-1 treatment owing to high incidence rates of adverse effects." | 1.36 | [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan]. ( Hazama, S; Nakazawa, S; Suga, T; Watanabe, S; Yagi, M; Yoshino, S, 2010) |
| " To expand the range of applications and investigate the clinical value of the combination strategy, the therapeutic benefit of metronomic S-1 dosing in combination with oxaliplatin (l-OHP)-containing PEG-coated liposomes was evaluated in a murine colon carcinoma-bearing mice model." | 1.36 | Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. ( Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Matsumoto, H; Okada, T, 2010) |
| "To investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of UFT and UZEL for metastatic colorectal carcinoma (mCRC), fourteen patients were enrolled in the present study." | 1.35 | Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. ( Hattori, T; Itoh, K; Komatsu, N; Mine, T; Okuno, K; Shiozaki, H; Yamada, A, 2009) |
| " Coadministration of S-1 changed the pharmacokinetic behavior of CPT-11 and its metabolites." | 1.35 | Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer. ( Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K, 2009) |
| "In advanced colorectal cancer (ACC), FOLFOX4 has been accepted as a standard chemotherapeutic regimen." | 1.34 | UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. ( Brugnatelli, S; Corazza, GR; Gattoni, E; Luchena, G; Riccardi, A; Sagrada, P; Scalamogna, R; Tinelli, C; Tronconi, MC, 2007) |
| " A dosage of 335 mg/m2/day of UFT was given perorally on daily schedule." | 1.34 | Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence. ( Akagi, Y; Fukushima, T; Ishibashi, N; Mori, S; Murakami, H; Ogata, Y; Shirouzu, K; Ushijima, M, 2007) |
| "The data on 307 patients with colorectal cancer at stage II or III, who underwent potentially curative resection with lymphadenectomy, were reviewed." | 1.33 | The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. ( Ikeda, S; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Ogo, S; Ohkita, A; Ozasa, H; Sasatomi, T; Shirouzu, K, 2006) |
| "A total of 30 colorectal cancer patients treated with the fluoropyrimidine-based combination S-1, all of whom had stage IV disease, were studied." | 1.32 | Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. ( Danenberg, KD; Danenberg, PV; Hayashi, K; Kawakami, K; Kuramochi, H; Schneider, S; Takasaki, K; Uchida, K; Yochim, JM, 2004) |
| "The subjects were 24 colorectal cancer patients." | 1.31 | A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients. ( Iwase, H; Kameya, T; Makuuchi, H; Sadahiro, S; Suzuki, T; Tajima, T, 2001) |
| "When tegafur was injected, the concentration of 5-FU in cancer tissue or lymphnodes was significantly higher than in normal tissue." | 1.30 | [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer]. ( Inamura, Y; Kanemitsu, T; Kojima, T; Miyashita, A; Naruse, T; Owa, Y; Suzumura, K, 1998) |
| "We measured the chemosensitivity of colorectal cancer to 5-FU by MTT assay using specimens from colonoscopy, and compared this with the histopathological effects." | 1.30 | [Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer]. ( Fujii, M; Imai, S; Mochizuki, F, 1999) |
| " A comparison of the prescribed dosage and patient records revealed a mean dose rate of 86." | 1.30 | [UFT-E granule compliance in postoperative adjuvant chemotherapy]. ( Hagiwara, M; Hanai, A; Kanasugi, K; Komoriyama, H; Yamaguchi, S, 1999) |
| " Rats were dosed p." | 1.29 | 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ( Baccanari, DP; Cao, S; Davis, ST; Joyner, SS; Rustum, YM; Spector, T, 1995) |
| "Evaluability of gastric and breast cancers was very low because of the poor growth of the grafts irrespective of the immunity of host animals." | 1.29 | [Evaluation of subrenal capsule assay (SRC) for clinical cancers]. ( Akao, S; Ishikawa, H; Iwami, N; Kiumi, F; Oya, M; Sasaki, K; Terada, H, 1996) |
| "Seventeen patients with colorectal cancer metastatic to the liver underwent hepatic resection." | 1.28 | Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis. ( Furusawa, M; Kakeji, Y; Maehara, Y; Sugimachi, K; Tomoda, H; Tsujitani, S; Watanabe, A, 1991) |
| "The cases were comprised of 9 gastric cancers, 6 colorectal cancers, 1 appendiceal carcinoma, and 1 malignant tumor of retroperitoneum, all of which were observed to have peritoneal dissemination during surgical operations." | 1.28 | [Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa]. ( Katsuki, Y; Nishimura, A; Tsuji, Y; Yasuda, T, 1990) |
| "These two cases showed no recurrent liver cancers." | 1.28 | [Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases]. ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (1.17) | 18.7374 |
| 1990's | 78 (18.22) | 18.2507 |
| 2000's | 184 (42.99) | 29.6817 |
| 2010's | 145 (33.88) | 24.3611 |
| 2020's | 16 (3.74) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, WC | 1 |
| Liu, YM | 1 |
| Liao, YH | 1 |
| Hsu, KC | 1 |
| Lien, ST | 1 |
| Chen, IC | 1 |
| Lai, MJ | 1 |
| Li, YH | 3 |
| Pan, SL | 1 |
| Chen, MC | 1 |
| Liou, JP | 1 |
| Ii, Y | 1 |
| Irie, T | 1 |
| Kobari, A | 1 |
| Kawaguchi, M | 1 |
| Momose, H | 1 |
| Tsukamoto, R | 1 |
| Kawai, M | 2 |
| Sugimoto, K | 1 |
| Kojima, Y | 1 |
| Arakawa, A | 1 |
| Terao, Y | 1 |
| Tomiki, Y | 1 |
| Sakamoto, K | 5 |
| Kobuchi, S | 1 |
| Tsuda, M | 4 |
| Okamura, M | 1 |
| Nakamura, T | 1 |
| Ito, Y | 2 |
| Okuda, H | 1 |
| Shimomura, M | 1 |
| Ikeda, S | 4 |
| Nakahara, M | 1 |
| Miguchi, M | 1 |
| Ishizaki, Y | 1 |
| Saitoh, Y | 1 |
| Toyota, K | 1 |
| Sumitani, D | 1 |
| Shimizu, Y | 1 |
| Takakura, Y | 1 |
| Shimizu, W | 1 |
| Yoshimitsu, M | 1 |
| Kodama, S | 1 |
| Fujimori, M | 1 |
| Oheda, M | 1 |
| Kobayashi, H | 1 |
| Ohdan, H | 1 |
| Miyashita, S | 1 |
| Shimizu, T | 5 |
| Ishizuka, M | 1 |
| Niki, M | 1 |
| Nishi, Y | 2 |
| Shibuya, N | 1 |
| Hachiya, H | 1 |
| Matsumoto, T | 2 |
| Sakuraoka, Y | 1 |
| Shiraki, T | 1 |
| Mori, S | 4 |
| Iso, Y | 1 |
| Irisawa, A | 1 |
| Aoki, T | 2 |
| Yu, YL | 1 |
| Tseng, WK | 1 |
| Liao, CK | 1 |
| Yeh, CY | 1 |
| Chen, HH | 1 |
| Liu, YH | 1 |
| Liaw, YW | 1 |
| Fan, CW | 1 |
| Aisu, N | 1 |
| Yoshida, Y | 1 |
| Komono, A | 1 |
| Sakamoto, R | 1 |
| Kojima, D | 1 |
| Hasegawa, S | 2 |
| Nakamoto, Y | 1 |
| Noda, M | 3 |
| Mikami, R | 1 |
| Tokunaga, Y | 4 |
| Okumoto, T | 1 |
| Kawamura, T | 1 |
| Fujiwara, H | 2 |
| Doi, S | 1 |
| Tomita, N | 4 |
| Toriu, N | 1 |
| Sawa, N | 1 |
| Imafuku, A | 1 |
| Hasegawa, E | 1 |
| Sekine, A | 1 |
| Mizuno, H | 2 |
| Yamanouchi, M | 1 |
| Hiramatsu, R | 1 |
| Hayami, N | 1 |
| Hoshino, J | 1 |
| Kawada, M | 1 |
| Suwabe, T | 1 |
| Ohashi, K | 1 |
| Fujii, T | 1 |
| Ubara, Y | 1 |
| Hong, XC | 1 |
| Liang, QL | 1 |
| Luo, XB | 1 |
| Hu, KH | 1 |
| Yang, HX | 1 |
| Ou, WT | 1 |
| Zhang, HJ | 1 |
| Sadahiro, S | 13 |
| Suzuki, T | 15 |
| Okada, K | 5 |
| Saito, G | 3 |
| Miyakita, H | 2 |
| Ogimi, T | 1 |
| Chan, LF | 2 |
| Kamei, Y | 2 |
| Masuishi, T | 2 |
| Taniguchi, H | 3 |
| Komori, A | 2 |
| Mitani, S | 1 |
| Narita, Y | 2 |
| Kadowaki, S | 2 |
| Ura, T | 2 |
| Ando, M | 1 |
| Muro, K | 10 |
| Takayama, T | 5 |
| Haga, I | 1 |
| Nakamura, A | 1 |
| Asami, K | 1 |
| Chen, TC | 1 |
| Jeng, YM | 1 |
| Liang, JT | 1 |
| Shiraiwa, K | 1 |
| Suzuki, Y | 1 |
| Uchida, H | 1 |
| Iwashita, Y | 1 |
| Tanaka, R | 2 |
| Iwao, M | 1 |
| Tada, K | 1 |
| Hirashita, T | 1 |
| Masuda, T | 1 |
| Endo, Y | 1 |
| Inomata, M | 1 |
| Itoh, H | 1 |
| Denda, T | 7 |
| Takashima, A | 2 |
| Gamoh, M | 4 |
| Iwanaga, I | 5 |
| Komatsu, Y | 13 |
| Takahashi, M | 4 |
| Nakamura, M | 6 |
| Ohori, H | 2 |
| Sakashita, A | 1 |
| Kobayashi, Y | 3 |
| Baba, H | 14 |
| Kotake, M | 2 |
| Ishioka, C | 4 |
| Yamada, Y | 16 |
| Sato, A | 5 |
| Yuki, S | 8 |
| Morita, S | 9 |
| Takahashi, S | 4 |
| Yamaguchi, T | 9 |
| Shimada, K | 8 |
| Nishizawa, Y | 1 |
| Haraguchi, N | 1 |
| Kim, H | 1 |
| Ide, Y | 2 |
| Nakata, K | 2 |
| Okamura, S | 2 |
| Kudo, T | 1 |
| Satoh, T | 5 |
| Uemura, M | 1 |
| Matsuda, C | 4 |
| Mizushima, T | 5 |
| Murata, K | 4 |
| Doki, Y | 4 |
| Eguchi, H | 1 |
| Kwakman, JJM | 3 |
| Simkens, LHJ | 2 |
| van Rooijen, JM | 2 |
| van de Wouw, AJ | 1 |
| Ten Tije, AJ | 1 |
| Creemers, GJM | 1 |
| Hendriks, MP | 2 |
| Los, M | 2 |
| van Alphen, RJ | 2 |
| Polée, MB | 2 |
| Muller, EW | 2 |
| van der Velden, AMT | 2 |
| van Voorthuizen, T | 2 |
| Koopman, M | 3 |
| Mol, L | 2 |
| van Werkhoven, E | 3 |
| Punt, CJA | 3 |
| Mukai, T | 1 |
| Uehara, K | 4 |
| Goto, H | 2 |
| Hiramatsu, K | 3 |
| Kobayashi, S | 3 |
| Sakamoto, E | 3 |
| Maeda, A | 4 |
| Takeuchi, E | 3 |
| Okada, Y | 2 |
| Ebata, T | 2 |
| Nagino, M | 4 |
| Franck, C | 1 |
| Malfertheiner, P | 1 |
| Venerito, M | 1 |
| Baars, A | 1 |
| van Zweeden, AA | 1 |
| de Mol, P | 1 |
| Kok, WEM | 1 |
| Miyake, Y | 3 |
| Nishimura, J | 1 |
| Kato, T | 16 |
| Ikeda, M | 4 |
| Tsujie, M | 2 |
| Hata, T | 3 |
| Takemasa, I | 3 |
| Yamamoto, H | 3 |
| Sekimoto, M | 3 |
| Nezu, R | 3 |
| Mori, M | 4 |
| Chionh, F | 1 |
| Lau, D | 1 |
| Yeung, Y | 1 |
| Price, T | 3 |
| Tebbutt, N | 1 |
| Li, J | 3 |
| Xu, R | 1 |
| Xu, J | 2 |
| Ikejiri, K | 1 |
| Shen, L | 2 |
| Toh, Y | 2 |
| Sakai, K | 2 |
| Yamamoto, M | 4 |
| Mishima, H | 6 |
| Wang, J | 2 |
| Baratelli, C | 1 |
| Tampellini, M | 1 |
| Di Maio, M | 1 |
| Ottone, A | 1 |
| Brizzi, MP | 1 |
| Forti, L | 1 |
| Alabiso, I | 1 |
| Sonetto, C | 1 |
| Alabiso, O | 1 |
| Scagliotti, GV | 1 |
| Kusumoto, T | 1 |
| Sunami, E | 1 |
| Ota, M | 1 |
| Yoshida, K | 7 |
| Sakamoto, Y | 4 |
| Mochizuki, I | 1 |
| Okabe, M | 1 |
| Kunieda, K | 1 |
| Yamauchi, J | 1 |
| Itabashi, M | 2 |
| Kotake, K | 2 |
| Takahashi, K | 6 |
| Boku, N | 9 |
| Aiba, K | 3 |
| Ishiguro, M | 2 |
| Sugihara, K | 11 |
| Shimodaira, H | 2 |
| Kobayashi, K | 4 |
| Miyamoto, Y | 5 |
| Naito, M | 1 |
| Chino, S | 1 |
| Ushiku, H | 1 |
| Kondo, Y | 2 |
| Kubo, H | 1 |
| Kaida, T | 1 |
| Yamashita, W | 1 |
| Takahashi, Y | 3 |
| Watanabe, M | 18 |
| Honda, M | 2 |
| Tanaka, C | 3 |
| Kondo, K | 3 |
| Takahashi, T | 12 |
| Kosugi, C | 2 |
| Takemoto, H | 2 |
| Kim, HM | 1 |
| Sakamoto, J | 3 |
| Oba, K | 3 |
| Kusano, M | 6 |
| Aoyama, T | 1 |
| Okabayashi, K | 5 |
| Hirata, K | 5 |
| Tsuji, Y | 2 |
| Nakamori, S | 2 |
| Asahara, T | 1 |
| Ohashi, Y | 2 |
| Yoshikawa, T | 1 |
| Saji, S | 2 |
| Hsu, TC | 1 |
| Wang, CC | 1 |
| Chen, Y | 1 |
| Wu, J | 1 |
| Cheng, K | 1 |
| Li, ZP | 1 |
| Luo, DY | 2 |
| Qiu, M | 1 |
| Gou, HF | 1 |
| Yi, C | 1 |
| Li, Q | 1 |
| Wang, X | 2 |
| Yang, Y | 1 |
| Cao, D | 1 |
| Shen, YL | 1 |
| Bi, F | 1 |
| Liu, JY | 1 |
| Tanioka, H | 2 |
| Morita, Y | 1 |
| Ishibashi, K | 2 |
| Kataoka, M | 1 |
| Satake, H | 1 |
| Munemoto, Y | 1 |
| van de Wouw, YAJ | 1 |
| Tije, AJT | 1 |
| Creemers, GM | 1 |
| Tanaka, A | 5 |
| Kajiwara, H | 1 |
| Nagase, H | 3 |
| Moriwaki, T | 4 |
| Sakai, Y | 2 |
| Ishida, H | 7 |
| Yamamoto, Y | 3 |
| Endo, S | 1 |
| Kuramochi, H | 6 |
| Sato, M | 2 |
| Hatachi, Y | 1 |
| Bando, Y | 1 |
| Maeba, T | 3 |
| Ikezawa, K | 1 |
| Shimada, M | 3 |
| Amagai, K | 3 |
| Morimoto, M | 1 |
| Tsuji, A | 9 |
| Nishina, T | 9 |
| Hyodo, I | 10 |
| Chen, J | 1 |
| Xu, T | 1 |
| Fukunaga, M | 5 |
| Uemura, Y | 1 |
| Fukuzaki, T | 2 |
| Ota, H | 2 |
| Ohue, M | 4 |
| Ohnishi, T | 1 |
| Tanaka, N | 1 |
| Neki, K | 1 |
| Kawahara, H | 7 |
| Watanabe, K | 6 |
| Toyama, Y | 4 |
| Akiba, T | 4 |
| Yanaga, K | 7 |
| McCleary, NJ | 1 |
| Meyerhardt, JA | 1 |
| Green, E | 1 |
| Yothers, G | 1 |
| de Gramont, A | 3 |
| Van Cutsem, E | 3 |
| O'Connell, M | 1 |
| Twelves, CJ | 1 |
| Saltz, LB | 3 |
| Haller, DG | 1 |
| Sargent, DJ | 1 |
| Di Bartolomeo, M | 2 |
| Pietrantonio, F | 1 |
| Perrone, F | 1 |
| Dotti, KF | 1 |
| Lampis, A | 1 |
| Bertan, C | 1 |
| Beretta, E | 1 |
| Rimassa, L | 1 |
| Carbone, C | 1 |
| Biondani, P | 1 |
| Passalacqua, R | 1 |
| Pilotti, S | 1 |
| Bajetta, E | 2 |
| Kamijo, A | 3 |
| Uchida, J | 6 |
| Kim, SY | 6 |
| S Hong, Y | 1 |
| K Shim, E | 1 |
| Kong, SY | 2 |
| Shin, A | 1 |
| Baek, JY | 3 |
| Jung, KH | 3 |
| Park, SR | 2 |
| Hong, YS | 6 |
| Lim, HS | 1 |
| Seong, MW | 1 |
| Park, YI | 1 |
| Enomoto, H | 3 |
| Sunaga, T | 1 |
| Suzuki, S | 1 |
| Kogo, M | 1 |
| Kurihara, T | 1 |
| Kaji, S | 1 |
| Koike, N | 1 |
| Harada, N | 1 |
| Suzuki, M | 1 |
| Kiuchi, Y | 1 |
| Takahari, D | 6 |
| Matsumoto, H | 8 |
| Yoshida, M | 5 |
| Iwamoto, S | 2 |
| Sasaki, Y | 6 |
| Sakata, Y | 7 |
| Shimada, Y | 11 |
| Totsuka, O | 1 |
| Kawate, S | 3 |
| Hirai, K | 3 |
| Ogawa, H | 1 |
| Toya, H | 1 |
| Yoshinari, D | 1 |
| Sunose, Y | 1 |
| Takeyoshi, I | 2 |
| Nakamura, H | 1 |
| Doi, Y | 3 |
| Abu Lila, AS | 4 |
| Nagao, A | 2 |
| Ishida, T | 6 |
| Kiwada, H | 4 |
| Sugiura, F | 4 |
| Inoue, K | 3 |
| Kogita, A | 2 |
| Yoshioka, Y | 2 |
| Hida, J | 3 |
| Okuno, K | 5 |
| Sukegawa, Y | 3 |
| Tomoda, M | 1 |
| Mizuta, M | 2 |
| Watanabe, R | 1 |
| Takahashi, I | 2 |
| Watanabe, Y | 5 |
| Lee, J | 5 |
| Shin, SJ | 5 |
| Chung, IJ | 3 |
| Kim, TW | 6 |
| Chun, HG | 1 |
| Shin, DB | 3 |
| Kim, YH | 2 |
| Song, HS | 1 |
| Han, SW | 3 |
| Kim, JG | 1 |
| Choi, YJ | 1 |
| Chung, HC | 3 |
| Bozkurt, O | 1 |
| Karaca, H | 1 |
| Ciltas, A | 1 |
| Kaplan, MA | 1 |
| Benekli, M | 1 |
| Sevinc, A | 1 |
| Demirci, U | 1 |
| Eren, T | 1 |
| Kodaz, H | 1 |
| Isikdogan, A | 1 |
| Ozkan, M | 1 |
| Buyukberber, S | 1 |
| Saiura, A | 3 |
| Yamamoto, J | 2 |
| Hasegawa, K | 6 |
| Oba, M | 3 |
| Miyagawa, S | 2 |
| Ijichi, M | 2 |
| Teruya, M | 2 |
| Yoshimi, F | 2 |
| Kawasaki, S | 2 |
| Koyama, H | 2 |
| Makuuchi, M | 2 |
| Kokudo, N | 4 |
| Yoshinaga, K | 1 |
| Saeki, H | 3 |
| Oki, E | 4 |
| Morita, M | 1 |
| Ikeda, T | 1 |
| Sugimachi, K | 4 |
| Yamashita, Y | 2 |
| Ikegami, T | 1 |
| Uchiyama, H | 1 |
| Yoshizumi, T | 1 |
| Soejima, Y | 1 |
| Kawanaka, H | 2 |
| Mimori, K | 1 |
| Maehara, Y | 6 |
| Komura, T | 1 |
| Miura, K | 2 |
| Shirasaka, T | 7 |
| Ohnuma, S | 1 |
| Kajiwara, T | 1 |
| Fujishima, F | 1 |
| Philchenkov, A | 1 |
| Nakagawa, K | 1 |
| Kudoh, K | 1 |
| Haneda, S | 1 |
| Toshima, M | 1 |
| Kohyama, A | 1 |
| Musha, H | 1 |
| Naitoh, T | 1 |
| Shibata, C | 1 |
| Unno, M | 1 |
| Takii, Y | 4 |
| Yamazaki, T | 1 |
| Okada, T | 3 |
| Tani, T | 1 |
| Funakoshi, K | 1 |
| Maruyama, S | 2 |
| Hasegawa, J | 2 |
| Akazawa, K | 1 |
| Hatakeyama, K | 2 |
| Lee, KW | 3 |
| Kim, YJ | 1 |
| Lee, KH | 4 |
| Kim, TY | 4 |
| Oh, DY | 3 |
| Im, SA | 2 |
| Bang, YJ | 2 |
| Choi, IS | 2 |
| Kim, JH | 5 |
| Hamaguchi, T | 6 |
| Mizusawa, J | 1 |
| Saito, N | 3 |
| Kanemitsu, Y | 1 |
| Takiguchi, N | 2 |
| Sato, T | 5 |
| Yamaguchi, S | 5 |
| Akaike, M | 3 |
| Kubo, Y | 1 |
| Nakamura, K | 2 |
| Fukuda, H | 1 |
| Moriya, Y | 2 |
| Yoshida, N | 1 |
| Higashi, D | 1 |
| Egawa, Y | 1 |
| Hirano, Y | 1 |
| Hirano, K | 2 |
| Miyake, T | 1 |
| Takahashi, H | 1 |
| Uwatoko, S | 1 |
| Abe, S | 1 |
| Yamamoto, S | 1 |
| Mikami, K | 2 |
| Futami, K | 3 |
| Maekawa, T | 2 |
| Inoue, R | 1 |
| Miyazaki, M | 1 |
| Yasui, H | 4 |
| Sameshima, S | 2 |
| Ina, K | 3 |
| Yamaguchi, K | 4 |
| Esaki, T | 6 |
| Tokunaga, S | 3 |
| Kuwano, H | 3 |
| Shigeta, K | 2 |
| Ishii, Y | 3 |
| Hasegawa, H | 4 |
| Kitagawa, Y | 4 |
| Hong, L | 1 |
| Guo, Z | 1 |
| Yu, H | 1 |
| Li, B | 1 |
| Si, T | 1 |
| Liu, C | 1 |
| Kim, ST | 1 |
| Lim, HY | 4 |
| Kim, KP | 3 |
| Cho, SH | 2 |
| Kang, HJ | 2 |
| Lee, JW | 2 |
| Jo, SJ | 2 |
| Park, YS | 5 |
| Yamazaki, K | 6 |
| Ojima, H | 1 |
| Otsuji, T | 1 |
| Shirao, K | 8 |
| Ohishi, T | 2 |
| Takeuchi, M | 1 |
| Maruo, H | 1 |
| Suzuki, K | 1 |
| Ishikawa, S | 1 |
| Murakami, T | 1 |
| Higashi, Y | 1 |
| Shoji, T | 1 |
| Yamazaki, M | 1 |
| Taniguchi, M | 2 |
| Nishiyama, R | 1 |
| Hamamoto, Y | 1 |
| Yoshino, T | 4 |
| Miyata, Y | 3 |
| Ohtsu, A | 5 |
| Tojima, Y | 2 |
| Yatsuya, H | 1 |
| Tamagawa, H | 1 |
| Sasaki, K | 4 |
| Ohge, H | 1 |
| Tsuchiya, T | 1 |
| Ogata, Y | 9 |
| Masuko, H | 1 |
| Maeda, K | 2 |
| Hamada, M | 1 |
| Nishimura, G | 2 |
| Taguri, M | 1 |
| Kodaira, S | 3 |
| Kroep, JR | 1 |
| Polee, M | 1 |
| van Groeningen, CJ | 1 |
| Beeker, A | 1 |
| Erdkamp, F | 1 |
| Weijl, N | 1 |
| van Bochove, A | 1 |
| Erjavec, Z | 1 |
| Kapiteijn, E | 1 |
| Stiggelbout, AM | 1 |
| Nortier, HW | 1 |
| Gelderblom, H | 1 |
| Lu, M | 1 |
| Wang, Y | 1 |
| Liu, W | 1 |
| Bai, C | 1 |
| Morimoto, T | 1 |
| Yata, Y | 1 |
| Yonenaga, Y | 1 |
| Hanaki, K | 1 |
| Mise, M | 1 |
| Higaside, S | 1 |
| Kanda, Y | 1 |
| Noda, H | 1 |
| Iwasa, S | 2 |
| Nagashima, K | 2 |
| Ichikawa, Y | 2 |
| Goto, A | 6 |
| Kato, K | 8 |
| Okita, NT | 3 |
| Nitta, S | 1 |
| Nomura, M | 1 |
| Andoh, M | 1 |
| Mori, K | 1 |
| Igarashi, Y | 1 |
| Emi, Y | 3 |
| Kabashima, A | 1 |
| Higashi, H | 1 |
| Ikebe, M | 1 |
| Shirabe, K | 1 |
| Beppu, T | 2 |
| Uchida, S | 1 |
| Takatsuki, M | 1 |
| Sakoda, M | 1 |
| Eguchi, S | 1 |
| Akagi, Y | 6 |
| Kakeji, Y | 3 |
| Natsugoe, S | 3 |
| Goto, R | 1 |
| Kurihara, M | 1 |
| Yang, ZH | 1 |
| Ren, J | 1 |
| Yi, LJ | 1 |
| Zheng, JH | 1 |
| Wei, H | 1 |
| Wang, ZQ | 1 |
| Zhang, DS | 1 |
| Xu, N | 1 |
| Deng, YH | 1 |
| Wang, FH | 1 |
| Luo, HY | 1 |
| Qiu, MZ | 2 |
| Xu, RH | 2 |
| Maekawa, S | 1 |
| Kitazono, M | 1 |
| Murakami, H | 3 |
| Shimokawa, M | 2 |
| Higashijima, J | 1 |
| Ozeki, M | 1 |
| Negoro, Y | 2 |
| Indo, S | 1 |
| Nakajima, G | 3 |
| Hiroshima, Y | 1 |
| Maruyama, T | 2 |
| Yasuda, K | 2 |
| Sako, A | 1 |
| Ueda, K | 2 |
| Okumura, M | 1 |
| Berretta, M | 1 |
| Di Francia, R | 1 |
| Ishikawa, T | 1 |
| Uetake, H | 5 |
| Murotani, K | 1 |
| Kobunai, T | 2 |
| Matsui, S | 1 |
| Tsuruta, M | 1 |
| Endo, T | 2 |
| Ochiai, H | 2 |
| Kondo, T | 2 |
| Akasu, T | 2 |
| Kojima, H | 1 |
| Matsuda, K | 1 |
| Komori, K | 1 |
| Yamauchi, K | 1 |
| Kokuryo, T | 1 |
| Yokoyama, Y | 1 |
| Yamaguchi, J | 1 |
| Ogawa, M | 4 |
| Anan, T | 2 |
| Okuma, M | 1 |
| Ichihara, K | 1 |
| Hasegawa, T | 1 |
| Arita, J | 1 |
| Shinozaki, E | 1 |
| Mizunuma, N | 2 |
| Matsuyama, Y | 2 |
| Winther, SB | 1 |
| Zubcevic, K | 1 |
| Qvortrup, C | 1 |
| Vestermark, LW | 1 |
| Jensen, HA | 1 |
| Krogh, M | 1 |
| Sorbye, H | 1 |
| Pfeiffer, P | 4 |
| Takagane, A | 1 |
| Nagata, N | 1 |
| Otsuka, K | 2 |
| Kagimura, T | 1 |
| Takaoka, T | 1 |
| Kimura, T | 1 |
| Shimoyama, R | 1 |
| Kawamoto, S | 1 |
| Goda, F | 1 |
| Miyamoto, H | 2 |
| Yoshizaki, K | 1 |
| Goji, T | 1 |
| Kitamura, S | 1 |
| Yano, H | 1 |
| Okamoto, K | 1 |
| Kimura, M | 1 |
| Okahisa, T | 1 |
| Muguruma, N | 1 |
| Niitsu, Y | 1 |
| Nozawa, H | 1 |
| Ishihara, S | 1 |
| Kawai, K | 2 |
| Murono, K | 1 |
| Otani, K | 1 |
| Nishikawa, T | 1 |
| Tanaka, T | 2 |
| Kiyomatsu, T | 1 |
| Hata, K | 1 |
| Watanabe, T | 5 |
| Koda, K | 1 |
| Miyauchi, H | 1 |
| Kaiho, T | 1 |
| Matsubara, H | 1 |
| Moriyoshi, N | 1 |
| Fukushima, M | 5 |
| Huang, CL | 2 |
| Wada, H | 2 |
| Narahara, H | 2 |
| Sugimoto, N | 1 |
| Yoshisue, K | 1 |
| Fujii, M | 5 |
| Kochi, M | 1 |
| Yin, J | 1 |
| Zhu, X | 1 |
| Liu, Y | 1 |
| Cao, J | 1 |
| Lu, F | 1 |
| Zuo, Y | 1 |
| Sheikh, HY | 2 |
| Valle, JW | 2 |
| Waddell, T | 1 |
| Palmer, K | 2 |
| Wilson, G | 2 |
| Sjursen, A | 2 |
| Craven, O | 2 |
| Swindell, R | 2 |
| Saunders, MP | 2 |
| Hoff, PM | 11 |
| Kopetz, S | 1 |
| Thomas, MB | 1 |
| Langleben, A | 1 |
| Rinaldi, D | 1 |
| Anthony, L | 1 |
| Wolff, RA | 1 |
| Lassere, Y | 4 |
| Abbruzzese, JL | 3 |
| Sakai, T | 1 |
| Hoshino, S | 1 |
| Shirakusa, T | 1 |
| Kim, BC | 1 |
| Park, JW | 1 |
| Choi, HS | 1 |
| Jeong, SY | 1 |
| Kim, DY | 1 |
| Hong, CW | 1 |
| Sohn, DK | 1 |
| Shiozawa, M | 2 |
| Sugano, N | 2 |
| Tsuchida, K | 2 |
| Morinaga, S | 2 |
| Sugimasa, Y | 1 |
| Kameyama, H | 1 |
| Nomura, T | 1 |
| Nakagawa, S | 1 |
| Yabusaki, H | 1 |
| Tsuchiya, Y | 1 |
| Nashimoto, A | 1 |
| Tanaka, O | 1 |
| Honda, T | 1 |
| Hirashima, Y | 2 |
| Matsubara, J | 2 |
| Shimoda, T | 2 |
| Idelevich, E | 1 |
| Greif, F | 1 |
| Mavor, E | 1 |
| Miller, R | 1 |
| Kashtan, H | 1 |
| Susmalian, S | 1 |
| Ariche, A | 1 |
| Brenner, B | 1 |
| Baruch, NB | 1 |
| Dinerman, M | 1 |
| Shani, A | 1 |
| Yoshimatsu, K | 2 |
| Yokomizo, H | 2 |
| Osawa, G | 1 |
| Fujimoto, T | 2 |
| Otani, T | 1 |
| Tsunoda, T | 2 |
| Nakamura, Y | 3 |
| Ogawa, K | 2 |
| Zang, DY | 2 |
| Lee, BH | 1 |
| Park, HC | 1 |
| Song, HH | 1 |
| Kim, HJ | 1 |
| Jung, JY | 1 |
| Kim, HY | 1 |
| Kwon, JH | 1 |
| Hwang, SW | 1 |
| Park, CH | 2 |
| Kim, KO | 1 |
| Kim, MJ | 1 |
| Jang, KM | 1 |
| Chayahara, N | 1 |
| Tamura, T | 1 |
| Yamamori, M | 1 |
| Kadowaki, Y | 1 |
| Okuno, T | 1 |
| Miki, I | 1 |
| Nishisaki, H | 1 |
| Maeda, T | 1 |
| Inoue, Y | 3 |
| Okumura, K | 1 |
| Azuma, T | 1 |
| Kasuga, M | 1 |
| Sakaeda, T | 1 |
| Hirai, M | 1 |
| Yoshitani, S | 1 |
| Takashima, S | 1 |
| Bennouna, J | 4 |
| Saunders, M | 1 |
| Douillard, JY | 6 |
| Maeda, Y | 5 |
| Ishikawa, K | 3 |
| Makuuchi, H | 7 |
| Murayama, C | 4 |
| Hattori, T | 3 |
| Mine, T | 1 |
| Komatsu, N | 1 |
| Yamada, A | 1 |
| Itoh, K | 1 |
| Shiozaki, H | 1 |
| Onozawa, Y | 1 |
| Hironaka, S | 1 |
| Fukutomi, A | 1 |
| Taku, K | 1 |
| Kojima, T | 2 |
| Machida, N | 1 |
| Yokoo, K | 2 |
| Hamada, A | 2 |
| Tazoe, K | 1 |
| Saito, H | 3 |
| Furukawa, H | 2 |
| Kim, HS | 2 |
| Park, MJ | 1 |
| Uhm, JE | 1 |
| Lee, Y | 1 |
| Lee, HY | 2 |
| Kang, EM | 1 |
| Park, SH | 3 |
| Park, JO | 3 |
| Kang, WK | 3 |
| Teng, KY | 1 |
| Ruan, DY | 1 |
| Chen, XQ | 1 |
| Pan, ZZ | 1 |
| He, YJ | 1 |
| Wan, DS | 1 |
| Tsunoda, A | 9 |
| Yasuda, N | 3 |
| Nakao, K | 8 |
| Narita, K | 4 |
| Matsui, N | 5 |
| Hibi, S | 1 |
| Furuta, R | 1 |
| Kataoka, T | 1 |
| Kojima, S | 1 |
| Koizumi, W | 1 |
| Sawaki, A | 1 |
| Furuhata, T | 3 |
| Miyashita, K | 2 |
| Meguro, M | 2 |
| Okita, K | 2 |
| Nishidate, T | 2 |
| Ishiyama, G | 2 |
| Iwayama, Y | 2 |
| Kimura, Y | 2 |
| Mizuguchi, T | 2 |
| Yoshioka, T | 1 |
| Kato, S | 2 |
| Chiba, N | 1 |
| Sakayori, N | 1 |
| Shibata, H | 1 |
| Kakudo, Y | 1 |
| Hiraki, M | 1 |
| Kitajima, Y | 1 |
| Nakafusa, Y | 1 |
| Nakamura, J | 1 |
| Hashiguchi, K | 1 |
| Sumi, K | 1 |
| Noshiro, H | 1 |
| Miyazaki, K | 1 |
| Hosokawa, Y | 1 |
| Tsuruma, T | 1 |
| Bin, Q | 1 |
| Liao, C | 1 |
| Cao, Y | 1 |
| Gao, F | 1 |
| Tsunoda, Y | 3 |
| Sasatomi, T | 2 |
| Ishibashi, N | 4 |
| Shirouzu, K | 4 |
| Oh, SY | 2 |
| Ju, YT | 1 |
| Choi, SK | 1 |
| Ha, CY | 1 |
| Lee, WS | 1 |
| Kim, HG | 1 |
| Lee, GW | 1 |
| Kwon, HC | 1 |
| Kang, JH | 1 |
| Jeong, JH | 1 |
| Shim, BY | 1 |
| Lee, MA | 1 |
| Kim, YT | 1 |
| Roh, JK | 3 |
| Ahn, JB | 3 |
| Yagi, M | 1 |
| Watanabe, S | 2 |
| Yoshino, S | 2 |
| Hazama, S | 2 |
| Suga, T | 1 |
| Nakazawa, S | 1 |
| Yasutome, M | 1 |
| Mori, T | 4 |
| Fukui, T | 1 |
| Mitsudomi, T | 1 |
| Yamamoto, N | 1 |
| Ooyama, A | 1 |
| Takiuchi, H | 3 |
| Ichihara, M | 2 |
| Hong, J | 1 |
| Ham, HS | 1 |
| Kim, BS | 1 |
| Kang, GH | 1 |
| Schmoll, HJ | 1 |
| Kusaba, H | 2 |
| Tanaka, S | 2 |
| Fujishima, H | 1 |
| Mitsugi, K | 2 |
| Ariyama, H | 1 |
| Kinugawa, N | 1 |
| Ueki, T | 1 |
| Mibu, R | 1 |
| Baba, E | 2 |
| Nakano, S | 1 |
| Akashi, K | 2 |
| Lee, DJ | 1 |
| Lim, T | 1 |
| Lee, SJ | 1 |
| Yi, SY | 1 |
| Molina-Garrido, MJ | 1 |
| Guillén-Ponce, C | 1 |
| Kadota, K | 1 |
| Liu, D | 1 |
| Yokomise, H | 1 |
| Haba, R | 1 |
| Shitara, K | 1 |
| Utsunomiya, S | 1 |
| Yokota, T | 1 |
| Sato, Y | 2 |
| Inaba, Y | 2 |
| Tajika, M | 1 |
| Kawai, H | 1 |
| Yamaura, H | 2 |
| Kato, M | 1 |
| Nishigaki, T | 1 |
| Kaneko, J | 1 |
| Isogai, J | 1 |
| Aoyagi, H | 1 |
| Katsuta, E | 1 |
| Someno, Y | 1 |
| Saguchi, M | 1 |
| Takahata, T | 1 |
| Hamada, S | 1 |
| Maejima, S | 1 |
| Choi, YH | 2 |
| Lee, SS | 2 |
| Ryu, MH | 2 |
| Lee, JL | 2 |
| Chang, HM | 2 |
| Kang, YK | 2 |
| Sogabe, S | 3 |
| Kusumi, T | 1 |
| Hatanaka, K | 2 |
| Miyagishima, T | 3 |
| Hosokawa, A | 2 |
| Asaka, M | 4 |
| Nakayama, G | 1 |
| Kodera, Y | 1 |
| Yokoyama, H | 1 |
| Okuda, N | 1 |
| Iwata, N | 1 |
| Ohashi, N | 1 |
| Koike, M | 1 |
| Fujiwara, M | 1 |
| Nakao, A | 1 |
| Jung, M | 1 |
| Jeung, HC | 2 |
| Kim, HR | 1 |
| Rha, SY | 3 |
| Fukushima, H | 2 |
| Kudo, M | 4 |
| Tateyama, M | 4 |
| Meguro, T | 3 |
| Uebayashi, M | 1 |
| Saga, A | 1 |
| Sasaki, H | 2 |
| Matsueda, S | 1 |
| Bellot, GL | 1 |
| Tan, WH | 1 |
| Tay, LL | 1 |
| Koh, D | 1 |
| Tokoro, T | 1 |
| Ishimaru, E | 1 |
| Yanagisawa, S | 1 |
| Nakatsumi, H | 1 |
| Munakata, M | 1 |
| Ryoo, BY | 1 |
| Shin, JG | 1 |
| Kobayashi, T | 1 |
| Eto, K | 1 |
| Oda, A | 1 |
| Hayashi, T | 1 |
| Mitsuyama, Y | 1 |
| Hisa, A | 1 |
| Nukatsuka, M | 2 |
| Nakagawa, F | 2 |
| Shiraishi, K | 1 |
| Takechi, T | 1 |
| Sakaguchi, K | 1 |
| Honma, Y | 1 |
| Francois, E | 4 |
| Smith, D | 2 |
| Dahan, L | 1 |
| Michel, C | 1 |
| Perrier, H | 3 |
| Mari, V | 1 |
| Seitz, JF | 3 |
| Follana, P | 1 |
| Evesque, L | 1 |
| Chamorey, E | 1 |
| Grothey, A | 1 |
| Okabe, H | 1 |
| Baba, Y | 1 |
| Iwatsuki, M | 1 |
| Chikamoto, A | 1 |
| Kishimoto, J | 1 |
| Uchino, K | 1 |
| Arita, S | 2 |
| Kumagai, H | 1 |
| Hashizume, T | 1 |
| Tango, T | 1 |
| Matsushita, N | 1 |
| Aruga, A | 1 |
| Kotera, Y | 1 |
| Takeda, K | 1 |
| Goto, M | 1 |
| Kii, T | 1 |
| Nishitani, H | 1 |
| Kawabe, S | 2 |
| Kuwakado, S | 1 |
| Asaishi, K | 1 |
| Miyamoto, T | 1 |
| Higuchi, K | 1 |
| Kim, K | 1 |
| Nam, E | 1 |
| Lee, NS | 1 |
| Lee, HR | 2 |
| Lee, JY | 1 |
| Song, SY | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Lee, MH | 1 |
| Lee, WY | 1 |
| Chun, H | 1 |
| Park, K | 1 |
| Friedman, M | 1 |
| Skillings, JR | 2 |
| Eisenberg, P | 1 |
| Davidson, N | 1 |
| Harper, P | 1 |
| Vincent, MD | 1 |
| Lembersky, BC | 1 |
| Thompson, S | 1 |
| Maniero, A | 1 |
| Benner, SE | 3 |
| Carmichael, J | 2 |
| Popiela, T | 1 |
| Radstone, D | 1 |
| Falk, S | 1 |
| Borner, M | 2 |
| Oza, A | 2 |
| Skovsgaard, T | 1 |
| Munier, S | 1 |
| Martin, C | 4 |
| Sugiyama, Y | 1 |
| Nakazato, H | 2 |
| Ito, K | 1 |
| Mizuno, I | 1 |
| Kanemitsu, T | 2 |
| Matsumoto, K | 1 |
| Yamaguchi, A | 4 |
| Nakai, K | 1 |
| Inada, K | 1 |
| Tatematsu, M | 1 |
| Eng, C | 1 |
| Kindler, HL | 1 |
| Schilsky, RL | 1 |
| Aranda, E | 4 |
| Antón-Torres, A | 1 |
| Sastre, J | 3 |
| Navarro, M | 3 |
| Rivera, F | 1 |
| Carrato, A | 3 |
| Bretón, JJ | 1 |
| Aparicio, J | 2 |
| Fernández-Martos, C | 2 |
| Díaz-Rubio, E | 4 |
| Maruyama, M | 2 |
| Ebuchi, M | 2 |
| Nagahama, T | 1 |
| Takashima, I | 2 |
| Ochiai, T | 1 |
| Natui, S | 1 |
| Kohnoe, S | 1 |
| Gotoh, M | 2 |
| Ohta, S | 1 |
| Katsu, K | 1 |
| Van den Brande, J | 1 |
| Schöffski, P | 3 |
| Schellens, JH | 1 |
| Roth, AD | 1 |
| Duffaud, F | 1 |
| Weigang-Köhler, K | 1 |
| Reinke, F | 1 |
| Wanders, J | 2 |
| de Boer, RF | 2 |
| Vermorken, JB | 1 |
| Fumoleau, P | 2 |
| Glimelius, B | 2 |
| Porschen, R | 1 |
| Mackay, HJ | 1 |
| Hill, M | 2 |
| Twelves, C | 3 |
| Glasspool, R | 1 |
| Campbell, S | 1 |
| Massey, A | 1 |
| Macham, MA | 1 |
| Uzzel, M | 1 |
| Bailey, SM | 1 |
| Cunningham, D | 3 |
| Ohwada, S | 3 |
| Ikeya, T | 2 |
| Yokomori, T | 2 |
| Kusaba, T | 2 |
| Roppongi, T | 2 |
| Nakamura, S | 2 |
| Kawashima, Y | 1 |
| Nakajima, T | 3 |
| Morishita, Y | 2 |
| Isomoto, H | 3 |
| Tomita, M | 4 |
| Yamada, K | 2 |
| Nakagoe, T | 5 |
| Takano, S | 2 |
| Kakegawa, T | 1 |
| Maroun, J | 2 |
| Asche, C | 1 |
| Romeyer, F | 1 |
| Mukherjee, J | 1 |
| Cripps, C | 1 |
| Skillings, J | 1 |
| Letarte, J | 1 |
| Taguchi, S | 1 |
| Ichikawa, W | 2 |
| Shirota, Y | 2 |
| Yamada, H | 5 |
| Nihei, Z | 2 |
| Hirayama, R | 2 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Katayanagi, S | 1 |
| Doi, T | 1 |
| Ward, S | 1 |
| Kaltenthaler, E | 2 |
| Cowan, J | 2 |
| Brewer, N | 1 |
| Shirakawa, K | 2 |
| Nakada, H | 3 |
| Ohsawa, T | 2 |
| Takeuchi, I | 2 |
| Okada, N | 1 |
| Yokoyama, M | 3 |
| Inokuma, S | 3 |
| Odaka, A | 2 |
| Hoshino, T | 1 |
| Murata, N | 2 |
| Hashimoto, D | 2 |
| Itoyama, S | 1 |
| Matsumoto, Y | 2 |
| Miura, T | 2 |
| Higuchi, T | 2 |
| Enomoto, M | 2 |
| Petrioli, R | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Marsili, S | 1 |
| Pozzessere, D | 1 |
| Messinese, S | 1 |
| Correale, P | 1 |
| Civitelli, S | 1 |
| Tanzini, G | 1 |
| Tani, F | 1 |
| De Martino, A | 1 |
| Marzocca, G | 1 |
| Lorenzi, M | 1 |
| Giorgi, G | 1 |
| Francini, G | 1 |
| Cats, A | 1 |
| Uchida, K | 5 |
| Hayashi, K | 5 |
| Kawakami, K | 3 |
| Schneider, S | 2 |
| Yochim, JM | 2 |
| Takasaki, K | 3 |
| Danenberg, KD | 3 |
| Danenberg, PV | 3 |
| Kakinuma, S | 1 |
| Iwazaki, S | 1 |
| Ishikawa, H | 7 |
| Funahashi, K | 1 |
| Koike, J | 1 |
| Miki, T | 1 |
| Ryu, M | 1 |
| Shiokawa, H | 1 |
| Tokuyama, T | 1 |
| Goto, T | 1 |
| Teramoto, T | 2 |
| Folprecht, G | 1 |
| Köhne, CH | 2 |
| Taïeb, J | 1 |
| Desramé, J | 1 |
| Artru, P | 2 |
| Takada, H | 1 |
| Mitachi, Y | 2 |
| Hirakawa, K | 1 |
| Horikoshi, N | 3 |
| Okamura, T | 1 |
| Saitoh, S | 1 |
| Satoh, A | 1 |
| Sakuyama, T | 1 |
| Takao, Y | 1 |
| Sato, K | 2 |
| Anazawa, S | 1 |
| Yamazaki, Y | 1 |
| Alliot, C | 2 |
| Gyldenkerne, N | 1 |
| Frödin, JE | 1 |
| Kjaer, M | 2 |
| Hansen, F | 3 |
| Keldsen, N | 2 |
| Sandberg, E | 3 |
| Jakobsen, A | 4 |
| Loehrer, PJ | 1 |
| Wadler, S | 1 |
| Wadleigh, RG | 1 |
| O'Dwyer, PJ | 1 |
| Nagashima, F | 1 |
| Chu, QS | 1 |
| Hammond, LA | 1 |
| Schwartz, G | 1 |
| Ochoa, L | 1 |
| Denis, L | 1 |
| Molpus, K | 1 |
| Roedig, B | 1 |
| Letrent, SP | 1 |
| Damle, B | 2 |
| DeCillis, AP | 1 |
| Rowinsky, EK | 1 |
| Labianca, R | 2 |
| Beretta, GD | 2 |
| Mosconi, S | 2 |
| Milesi, L | 1 |
| Scheithauer, W | 2 |
| Feliu, J | 3 |
| Vicent, JM | 1 |
| García-Girón, C | 2 |
| Constela, M | 1 |
| Fonseca, E | 1 |
| Lomas, M | 1 |
| Antón-Aparicio, L | 1 |
| Dorta, FJ | 1 |
| Gonzalez-Baron, M | 2 |
| Katsuno, H | 1 |
| Utsumi, T | 2 |
| Hanai, T | 1 |
| Sato, H | 1 |
| Masumori, K | 1 |
| Koide, Y | 1 |
| Matsumoto, M | 2 |
| Koide, A | 1 |
| Ohbu, M | 1 |
| Mushiake, H | 1 |
| Shimao, K | 1 |
| Tahara, H | 1 |
| Iida, S | 1 |
| Tsunozaki, H | 1 |
| Yasuno, M | 1 |
| Yuuki, S | 1 |
| Fuse, N | 1 |
| Takei, M | 1 |
| Kunieda, Y | 1 |
| Wakahama, O | 1 |
| Ohizumi, H | 1 |
| Akita, H | 1 |
| Nakano, K | 1 |
| Koizumi, H | 1 |
| Okugawa, K | 1 |
| Osaka, Y | 1 |
| Tsuchiya, K | 2 |
| Sako, H | 1 |
| Tanabe, S | 1 |
| Nakane, Y | 1 |
| Lima, AP | 1 |
| del Giglio, A | 1 |
| Yang, D | 1 |
| Méndez, M | 2 |
| Alfonso, PG | 1 |
| Pujol, E | 1 |
| González, E | 1 |
| Castañon, C | 1 |
| Cerezuela, P | 1 |
| López-Mateos, Y | 1 |
| Cruz, JJ | 1 |
| Kono, T | 1 |
| Ebisawa, Y | 1 |
| Tomita, I | 1 |
| Chisato, N | 1 |
| Kamiya, K | 1 |
| Asama, T | 1 |
| Ayabe, T | 1 |
| Ashida, T | 1 |
| Kohgo, Y | 1 |
| Kasai, S | 1 |
| Muneoka, K | 1 |
| Shirai, Y | 1 |
| Wakai, T | 1 |
| Yokoyama, N | 1 |
| Okumura, S | 1 |
| Kabeshima, Y | 1 |
| Kameyama, N | 1 |
| Toizumi, A | 1 |
| Tamura, Y | 1 |
| Kageyama, T | 1 |
| Matsumoto, S | 1 |
| Kawashima, K | 1 |
| Fujii, H | 1 |
| Hatano, E | 1 |
| Satoh, S | 1 |
| Ikai, I | 1 |
| Shimahara, Y | 1 |
| Rosati, G | 1 |
| Cordio, S | 1 |
| Tucci, A | 1 |
| Blanco, G | 1 |
| Bordonaro, R | 1 |
| Reggiardo, G | 1 |
| Manzione, L | 1 |
| Matono, K | 2 |
| Ohkita, A | 1 |
| Mizobe, T | 2 |
| Ogo, S | 1 |
| Ozasa, H | 2 |
| Nogué, M | 2 |
| Salud, A | 1 |
| Batiste-Alentorn, E | 2 |
| Saigí, E | 2 |
| Losa, F | 1 |
| Cirera, L | 1 |
| Campos, JM | 1 |
| Galan, A | 1 |
| Escudero, P | 3 |
| Arcusa, A | 2 |
| Manzano, H | 1 |
| de Mendizábal, EV | 1 |
| de Olaguer, JP | 1 |
| Boleda, M | 2 |
| Guasch, I | 1 |
| Vicente, P | 1 |
| Shimizu, R | 1 |
| Fukuda, S | 1 |
| Kudoh, A | 1 |
| Mizuta, E | 1 |
| Ogura, Y | 1 |
| Sano, A | 1 |
| Oka, M | 1 |
| Umehara, A | 1 |
| Toyokawa, A | 1 |
| Tsujimura, T | 1 |
| Hamabe, Y | 1 |
| Sato, S | 1 |
| Mukubou, H | 1 |
| Wakahara, T | 1 |
| Kaji, M | 1 |
| Tsukamoto, T | 1 |
| Wakita, K | 1 |
| Onishi, N | 1 |
| Watanabe, A | 2 |
| Mukai, H | 1 |
| Paillot, B | 1 |
| Priou, F | 1 |
| Jacob, JH | 1 |
| Hebbar, M | 1 |
| Bordenave, S | 1 |
| Cvitkovic, F | 1 |
| Dorval, E | 1 |
| Malek, K | 1 |
| Tonelli, D | 1 |
| Goyle, S | 1 |
| Maraveyas, A | 1 |
| Ogawa, T | 2 |
| Makita, F | 1 |
| Tanahashi, Y | 1 |
| Ohya, T | 1 |
| Tomizawa, N | 1 |
| Satoh, Y | 1 |
| Kobayashi, I | 1 |
| Izumi, M | 1 |
| Hamada, K | 1 |
| Minaguchi, S | 1 |
| Togo, Y | 1 |
| Toshihiko, T | 1 |
| Koyama, T | 1 |
| Kamio, M | 1 |
| Abad, A | 3 |
| Cervantes, A | 2 |
| Tabernero, J | 1 |
| Ward, SE | 1 |
| Marples, M | 1 |
| Orr, B | 1 |
| Seymour, MT | 1 |
| Yoshioka, K | 1 |
| Ito, T | 1 |
| Hoki, M | 1 |
| Souma, Y | 1 |
| Iwamoto, T | 1 |
| Ozawa, H | 1 |
| Kanou, T | 1 |
| Nakamori, Y | 1 |
| Iwase, K | 1 |
| Nakata, E | 1 |
| Takai, Y | 1 |
| Nemoto, K | 1 |
| Ogawa, Y | 1 |
| Nomiya, T | 1 |
| Milas, L | 1 |
| Yamada, S | 1 |
| Segura, C | 1 |
| Afchain, P | 1 |
| André, T | 1 |
| Eguchi, T | 1 |
| Kamiyama, G | 1 |
| Suzuki, N | 2 |
| Oonaka, T | 1 |
| Arai, Y | 1 |
| Takeuchi, Y | 1 |
| Aramaki, T | 1 |
| Seki, H | 1 |
| Matsueda, K | 1 |
| Watanabe, H | 1 |
| Masa, K | 1 |
| Terazaki, H | 1 |
| Cho, BC | 1 |
| Yoo, NC | 1 |
| Roh, WJ | 1 |
| Lin, PC | 1 |
| Chen, WS | 1 |
| Chao, TC | 1 |
| Yang, SH | 1 |
| Tiu, CM | 1 |
| Liu, JH | 1 |
| Buzzoni, R | 1 |
| Mariani, L | 1 |
| Zilembo, N | 1 |
| Ferrario, E | 1 |
| Lo Vullo, S | 1 |
| Aitini, E | 1 |
| Isa, L | 1 |
| Barone, C | 1 |
| Jacobelli, S | 1 |
| Recaldin, E | 1 |
| Pinotti, G | 1 |
| Iop, A | 1 |
| Saito, T | 1 |
| Tsujimoto, H | 1 |
| Tsukioka, S | 1 |
| Koizumi, K | 1 |
| Sugimoto, Y | 1 |
| Oka, T | 1 |
| Ogata, K | 1 |
| Ohchi, T | 1 |
| Doi, K | 1 |
| Matsuo, A | 1 |
| Kudo, K | 1 |
| Ootao, R | 1 |
| Almond, J | 1 |
| Ralston, S | 1 |
| Delord, JP | 1 |
| Husseini, F | 1 |
| Desseigne, F | 1 |
| Faroux, R | 1 |
| Piedbois, P | 1 |
| Naman, H | 1 |
| Bugat, R | 1 |
| Etienne-Grimaldi, MC | 2 |
| Cardot, JM | 2 |
| Renée, N | 3 |
| Gamelin, E | 2 |
| Milano, G | 3 |
| Uedo, N | 1 |
| Ishihara, R | 1 |
| Château, Y | 1 |
| Tanaka, Y | 1 |
| Yasuda, S | 2 |
| Isogai, A | 1 |
| Nagaya, M | 1 |
| Matsuoka, H | 1 |
| Tsukikawa, S | 3 |
| Kubota, S | 1 |
| Hochster, HS | 1 |
| Luo, W | 1 |
| Popa, EC | 1 |
| Lyman, BT | 1 |
| Mulcahy, M | 1 |
| Beatty, PA | 1 |
| Benson, AB | 1 |
| Geboes, K | 1 |
| Scalamogna, R | 1 |
| Brugnatelli, S | 1 |
| Tinelli, C | 1 |
| Sagrada, P | 1 |
| Gattoni, E | 1 |
| Tronconi, MC | 1 |
| Riccardi, A | 1 |
| Luchena, G | 1 |
| Corazza, GR | 1 |
| Hatori, T | 1 |
| Ushijima, M | 1 |
| Fukushima, T | 2 |
| Hosotaki, K | 1 |
| Tabira, Y | 1 |
| Shimamoto, M | 1 |
| Tamori, Y | 1 |
| Kubota, T | 1 |
| Omura, K | 2 |
| Kanehira, E | 1 |
| Nagasato, A | 1 |
| Kawashima, S | 1 |
| Tawaraya, K | 1 |
| Leichman, CG | 1 |
| Young, CW | 1 |
| Muggia, FM | 1 |
| Conti, JA | 1 |
| Spiess, T | 1 |
| Jeffers, S | 1 |
| Leichman, LP | 1 |
| Hisikawa, E | 1 |
| Yaguchi, H | 1 |
| Arima, H | 1 |
| Hachisu, T | 1 |
| Kashiwabara, H | 1 |
| Yokoyama, T | 1 |
| Yamamura, T | 4 |
| Oikawa, H | 1 |
| Hanai, A | 2 |
| Matsuzaki, H | 1 |
| Akaishi, O | 1 |
| Seo, K | 1 |
| Kikuchi, K | 2 |
| Ozasa, T | 1 |
| Moriguchi, M | 1 |
| Seki, N | 1 |
| Higaki, T | 1 |
| Oishi, H | 1 |
| Nakata, Y | 1 |
| Kono, S | 1 |
| Pazdur, R | 11 |
| Rhodes, V | 1 |
| Ajani, JA | 1 |
| Sugarman, SM | 1 |
| Patt, YZ | 1 |
| Jones, DV | 1 |
| Markowitz, AB | 1 |
| Bready, B | 2 |
| Ashikaga, K | 1 |
| Kimura, C | 1 |
| Kuroda, H | 1 |
| Ono, M | 1 |
| Yoshikawa, K | 1 |
| Hashimoto, T | 2 |
| Dousei, T | 1 |
| Moriguchi, S | 1 |
| Ueda, H | 1 |
| Taketani, S | 1 |
| Suhara, H | 1 |
| Creaven, PJ | 2 |
| Rustum, YM | 7 |
| Petrelli, NJ | 1 |
| Gorbunova, VA | 3 |
| Manzuik, LV | 1 |
| Perevodchikova, NI | 2 |
| Singin, AS | 1 |
| Gerasimova, GS | 1 |
| Bychkov, MB | 1 |
| Shimoyama, T | 3 |
| Kusano, H | 3 |
| Nakazaki, T | 1 |
| Yasutake, T | 1 |
| Yoshida, A | 1 |
| Fujita, F | 2 |
| Fujita, M | 2 |
| Inaba, H | 1 |
| Taguchi, T | 7 |
| Ishida, F | 1 |
| Matsu, T | 1 |
| Adachi, I | 1 |
| Cao, S | 4 |
| Baccanari, DP | 1 |
| Joyner, SS | 1 |
| Davis, ST | 1 |
| Spector, T | 1 |
| Michiwa, Y | 1 |
| Yagi, H | 1 |
| Fushida, S | 1 |
| Fugimura, T | 1 |
| Sugiyama, K | 1 |
| Kanno, M | 1 |
| Yonemura, Y | 2 |
| Miwa, K | 2 |
| Miyazaki, I | 2 |
| de la Gándara, I | 1 |
| Espinosa, E | 2 |
| Colmenarejo, A | 2 |
| Martínez-Martínez, B | 1 |
| Blanco, E | 2 |
| Juárez, F | 2 |
| Garrido, P | 1 |
| Akao, S | 2 |
| Iwami, N | 2 |
| Oya, M | 1 |
| Terada, H | 1 |
| Kiumi, F | 2 |
| Manziuk, LV | 1 |
| Luk'ianchenko, AB | 1 |
| Abramova, NA | 1 |
| Ikeda, E | 1 |
| Okuda, M | 1 |
| Ron, IG | 1 |
| Lotan, A | 1 |
| Inbar, MJ | 1 |
| Chaitchik, S | 1 |
| González Barón, M | 1 |
| Garcia Girón, C | 1 |
| Espinosa, J | 1 |
| Martinez, B | 1 |
| Crespo, MC | 1 |
| Ordóñez, A | 1 |
| de Castro, J | 1 |
| Isla, MD | 2 |
| Mayordomo, JI | 2 |
| Cajal, R | 1 |
| Sáenz, A | 2 |
| Tres, A | 2 |
| Diaz-Canton, E | 1 |
| Ho, DH | 1 |
| Sakamoto, S | 2 |
| Kawachi, Y | 2 |
| Iwama, T | 2 |
| Tsukada, K | 1 |
| Sagara, T | 2 |
| Murakami, S | 1 |
| Kudo, H | 2 |
| Okayasu, I | 1 |
| Mitsuishi, K | 1 |
| Umeno, T | 1 |
| Kimura, H | 1 |
| Fuchino, Y | 1 |
| Tomita, A | 1 |
| Meropol, NJ | 5 |
| Noel, D | 2 |
| Sonnichsen, DS | 2 |
| Birkhofer, MJ | 2 |
| Marcuello, E | 2 |
| Gallén, M | 2 |
| Murad, A | 1 |
| de Andrade, CA | 1 |
| Delfino, C | 1 |
| Arikian, S | 1 |
| Doyle, J | 1 |
| Sinha, N | 1 |
| Suzumura, K | 1 |
| Miyashita, A | 1 |
| Inamura, Y | 1 |
| Owa, Y | 1 |
| Naruse, T | 1 |
| Seguí, MA | 1 |
| Antón, I | 1 |
| Punt, CJ | 1 |
| Sulkes, A | 2 |
| Canetta, RM | 1 |
| Frank, C | 1 |
| Shimamoto, Y | 1 |
| Yonekura, R | 1 |
| Ohshimo, H | 1 |
| Seki, M | 1 |
| Ohta, H | 1 |
| Azekura, K | 1 |
| Ueno, M | 1 |
| Moroguchi, A | 1 |
| Matsubara, T | 1 |
| Canetta, R | 1 |
| Ferreira, I | 2 |
| Lu, K | 1 |
| Tóth, K | 1 |
| Slocum, HK | 1 |
| Rubiales, AS | 1 |
| del Valle, ML | 1 |
| Brito, RA | 1 |
| Medgyesy, D | 3 |
| Zukowski, TH | 2 |
| Royce, ME | 3 |
| Ravandi-Kashani, F | 1 |
| Rifá, J | 1 |
| Massuti, T | 1 |
| Antón, A | 2 |
| Fernández Martos, C | 1 |
| Ollendorf, D | 1 |
| Okazaki, M | 1 |
| Denno, R | 1 |
| Nakano, Y | 1 |
| Ishizuka, H | 1 |
| Uno, S | 1 |
| Imai, S | 1 |
| Mochizuki, F | 1 |
| Komoriyama, H | 1 |
| Kanasugi, K | 1 |
| Hagiwara, M | 1 |
| Adjei, AA | 1 |
| Fujioka, M | 1 |
| Kishi, T | 1 |
| Shimomura, K | 1 |
| Idezuki, Y | 1 |
| Kamano, T | 1 |
| Royce, M | 1 |
| Brito, R | 1 |
| Cvitkovic, E | 1 |
| Bekradda, M | 1 |
| Suzuka, I | 1 |
| Izumi, S | 1 |
| Onoda, Y | 1 |
| Shiota, K | 1 |
| Nishihara, M | 1 |
| Nakagawa, J | 1 |
| Shimizu, N | 1 |
| Matsuura, T | 1 |
| Fukuda, Y | 2 |
| Fujitaka, T | 1 |
| Nishisaka, T | 1 |
| Sakatani, T | 1 |
| Ito, H | 1 |
| Sawai, T | 1 |
| Tsuji, T | 1 |
| Ayabe, H | 1 |
| Eida, K | 4 |
| Nogawa, T | 2 |
| Kunisaki, T | 1 |
| Tobinaga, K | 2 |
| Furukawa, M | 1 |
| Ino, M | 1 |
| Damjanov, N | 1 |
| Thongprasert, S | 1 |
| Maoleekoonpairoj, S | 1 |
| Laohavinij, S | 1 |
| Thavichaigarn, P | 1 |
| Kusunoki, M | 2 |
| Yanagi, H | 2 |
| Yoshikawa, R | 2 |
| Bissett, D | 1 |
| Ahmed, F | 1 |
| McLeod, H | 1 |
| Cassidy, J | 1 |
| Ohki, S | 1 |
| Otani, Y | 1 |
| Takemiya, S | 1 |
| Nagasaki, H | 1 |
| Nishiyama, K | 1 |
| Hiki, Y | 1 |
| Kumada, K | 1 |
| Shimada, H | 1 |
| Mitomi, T | 1 |
| Louvet, C | 1 |
| Coudray, AM | 1 |
| Tournigand, C | 1 |
| Prévost, S | 1 |
| Raymond, E | 1 |
| Chazard, M | 2 |
| Gespach, C | 1 |
| Sobrero, A | 1 |
| Guglielmi, A | 1 |
| Grossi, F | 1 |
| Puglisi, F | 1 |
| Aschele, C | 1 |
| Peeters, M | 1 |
| Bastian, G | 1 |
| Moutardier, V | 1 |
| Delperro, JR | 1 |
| Fargeot, P | 1 |
| Fraisse, J | 1 |
| Formento, P | 1 |
| Schilling, G | 1 |
| Lipp, R | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| Tokunaga, N | 1 |
| Ishizu, K | 1 |
| Tajima, T | 2 |
| Lewis, NL | 1 |
| Todnem, K | 1 |
| Harboe, K | 1 |
| Zotova, L | 1 |
| Lind, A | 1 |
| Ogreid, D | 1 |
| Sasaki, T | 1 |
| Shatari, T | 1 |
| Nozawa, K | 1 |
| Dwivedy, S | 1 |
| Sun, W | 1 |
| Haller, D | 1 |
| Furuyama, JI | 1 |
| Hashimoto-Tamaoki, T | 1 |
| Ravandi, F | 1 |
| Kaul, S | 1 |
| Sonnichsen, D | 1 |
| Brooks, D | 1 |
| Stewart, D | 1 |
| Alberts, D | 1 |
| James, RD | 1 |
| Aabo, K | 2 |
| Kameya, T | 1 |
| Iwase, H | 1 |
| Tsukuda, M | 1 |
| Inuyama, Y | 1 |
| Pessi, MA | 1 |
| Poletti, P | 1 |
| Coleman, R | 1 |
| Wilke, H | 1 |
| Reimer, P | 1 |
| Rückle-Lanz, H | 1 |
| Alonso, V | 1 |
| Zorrilla, M | 1 |
| Herrero, A | 1 |
| Martinez-Trufero, J | 1 |
| Chakrapee-Sirisuk, S | 1 |
| Sinlarat, P | 1 |
| Lohsiriwat, D | 1 |
| Lert-Akayamanee, N | 1 |
| Nimmanwudipong, T | 1 |
| Srimuninnimit, V | 1 |
| Vathanophas, V | 1 |
| Arch-Yaemsuan, P | 1 |
| Boonnuch, W | 1 |
| Borner, MM | 1 |
| de Wit, R | 1 |
| Caponigro, F | 1 |
| Comella, G | 1 |
| Greim, G | 1 |
| Peters, GJ | 1 |
| van der Born, K | 1 |
| Holen, KD | 1 |
| Koike, A | 1 |
| Suzuki, H | 1 |
| Takagi, H | 1 |
| Nimura, Y | 1 |
| Hasumi, A | 1 |
| Baba, S | 1 |
| Manabe, T | 1 |
| Maruta, M | 1 |
| Croockewit, AJ | 1 |
| de Boer, JE | 1 |
| van Loenhout, JW | 1 |
| Koopmans, PP | 1 |
| Adimi, P | 1 |
| Inaba, S | 1 |
| Ogino, A | 1 |
| Umeda, T | 1 |
| Ueda, Y | 1 |
| Ismail Ali, A | 1 |
| Simadibrata, R | 1 |
| Aziz Rani, A | 1 |
| Chudahman, M | 1 |
| Dharmika, D | 1 |
| Hirano, T | 3 |
| Ishii, T | 3 |
| Kotake, Y | 3 |
| Matsuda, T | 1 |
| Yasutomi, M | 1 |
| Kasai, Y | 1 |
| Abe, O | 1 |
| Inokuchi, K | 1 |
| Komi, N | 1 |
| Tsujitani, S | 1 |
| Tomoda, H | 1 |
| Furusawa, M | 1 |
| Arima, S | 1 |
| Yoshimura, S | 1 |
| Okamoto, T | 1 |
| Yamasaki, K | 1 |
| Koto, T | 1 |
| Yamasaki, S | 1 |
| Kawahara, K | 1 |
| Ikuno, T | 1 |
| Takeda, S | 1 |
| Palmeri, S | 1 |
| Gebbia, V | 1 |
| Russo, A | 1 |
| Armata, MG | 1 |
| Gebbia, N | 1 |
| Rausa, L | 1 |
| Nishimura, A | 1 |
| Katsuki, Y | 1 |
| Yasuda, T | 1 |
| Kawano, N | 1 |
| Houjo, K | 1 |
| Malik, ST | 1 |
| Talbot, D | 1 |
| Clarke, PI | 1 |
| Osborne, R | 1 |
| Reznek, R | 1 |
| Wrigley, PF | 1 |
| Slevin, ML | 1 |
| Hase, S | 1 |
| Yoshimura, A | 1 |
| Haruyama, K | 1 |
| Katsura, Y | 1 |
| Sameshima, T | 1 |
| Niwa, K | 1 |
| Ishizawa, T | 1 |
| Shimazu, H | 1 |
| Namba, M | 1 |
| Muto, K | 1 |
| Ikeguchi, S | 1 |
| Shida, S | 1 |
| Kuwa, K | 1 |
| Kawasaki, T | 1 |
| Kasahara, N | 1 |
| Okamoto, R | 1 |
| Kosaka, T | 1 |
| Takegawa, S | 1 |
| Oyama, S | 1 |
| Nishiyama, M | 1 |
| Takagami, S | 1 |
| Kirihara, Y | 1 |
| Saeki, T | 1 |
| Hirabayashi, N | 1 |
| Nosoh, Y | 1 |
| Niimoto, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines[NCT01918852] | Phase 3 | 161 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535] | Phase 3 | 710 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer[NCT00284258] | Phase 2/Phase 3 | 426 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer[NCT00677443] | Phase 3 | 344 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer[NCT01110941] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Randomized Phase II Study of Oxaliplatin and S-1 (SOX) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Peritoneal Metastasis of Colorectal Cancer[NCT02870153] | Phase 2 | 60 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer[NCT02090153] | Phase 2 | 39 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer[NCT00569790] | Phase 2 | 53 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer[NCT00497107] | Phase 3 | 300 participants (Anticipated) | Interventional | 2007-07-31 | Recruiting | ||
| A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer[NCT00385970] | Phase 3 | 380 participants (Anticipated) | Interventional | 2006-03-31 | Active, not recruiting | ||
| A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00531245] | Phase 1/Phase 2 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer[NCT00212589] | Phase 3 | 60 participants | Interventional | 2002-12-31 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer[NCT00004860] | Phase 2 | 0 participants | Interventional | 2000-10-09 | Completed | ||
| A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707] | Phase 2 | 55 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
66 reviews available for tegafur and Colorectal Cancer
| Article | Year |
|---|---|
Oral versus intravenous fluoropyrimidines for colorectal cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuva | 2017 |
Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-Free Sur | 2019 |
Efficacy of S-1 in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2014 |
The role of UFT in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Tegafur; Uracil | 2009 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
[Postoperative adjuvant chemotherapy for lung, gastric, colorectal and breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 2010 |
Oral fluoropyrimidine treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2001 |
[Progress in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2002 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inh | 2003 |
Practical considerations in the use of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color | 2003 |
[Oral fluoropyrimidines in the treatment of colorectal carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
[Controversy of treatment for advanced colorectal cancer--intermedisine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2003 |
[Tegafur.uracil for treatment of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug R | 2003 |
[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
[Effect of systemic chemotherapy by 5-FU with low dose CDDP (in the hospital) and UFT with low dose CDDP (in outpatient clinic) in unresectable recurrent colorectal cancer].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2003 |
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycyt | 2003 |
[Chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2003 |
The role of new agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2004 |
[Oral 5-FU and digestive cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2004 |
The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Hu | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deo | 2004 |
[Second-line chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2005 |
[Evaluation of pre-operative administration of TS-1 in patients with advanced gastric or colorectal cancer--estimation of pathological effectiveness for postoperative adjuvant chemotherapy with TS-1].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2005 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neop | 2005 |
[Adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug C | 2006 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Ana | 2006 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capeci | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2006 |
[Hepatic arterial infusion chemotherapy for liver metastases from digestive cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug | 2006 |
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Com | 2007 |
[Combined chemotherapy with 5-FU+cis-platin or UFT+cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colorectal Neop | 1995 |
Clinical studies of the modulation of Ftorafur.
Topics: Clinical Trials as Topic; Colorectal Neoplasms; Humans; Immunologic Factors; Japan; Molecular Struct | 1993 |
Intraarterial infusion chemotherapy for unresectable hepatic metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 1996 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt | 1998 |
Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer.
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical T | 1998 |
UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1998 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 1998 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neopla | 1999 |
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates; | 1999 |
New drugs in therapy of colorectal cancer: preclinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydro | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydro | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 1999 |
Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 1999 |
Oral therapy for colorectal cancer: how to choose.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Availabilit | 2000 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 2000 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluoroura | 2000 |
Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Folic Acid Antagonists; Humans; | 2000 |
Oral fluoropyrimidines in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
[Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2000 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Tria | 2000 |
[Recent advances is surgical adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cl | 2000 |
UFT in the treatment of colorectal and breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2001 |
[New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal | 2001 |
New drugs and combinations in the palliative treatment of colon and rectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colo | 2001 |
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2001 |
Answering patients' needs: oral alternatives to intravenous therapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Tria | 2001 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2002 |
209 trials available for tegafur and Colorectal Cancer
| Article | Year |
|---|---|
A prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2023 |
Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study).
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Combinations; Fem | 2019 |
Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop | 2020 |
Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma.
Topics: Colorectal Neoplasms; Drug Combinations; Drugs, Chinese Herbal; Humans; Maintenance Chemotherapy; Ne | 2020 |
Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2020 |
Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2020 |
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2021 |
Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop | 2021 |
Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
Topics: Aged; Capecitabine; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Oxonic Acid; Tega | 2017 |
Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug | 2017 |
Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2018 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col | 2017 |
MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Disea | 2018 |
Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2018 |
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Diarrhea; D | 2018 |
A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2018 |
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Me | 2019 |
Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2019 |
Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm | 2019 |
Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2019 |
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2013 |
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2013 |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptoth | 2013 |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydro | 2013 |
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
[Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined | 2013 |
[Treatment outcome of peptide vaccination for advanced colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; Female; | 2013 |
Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian | 2015 |
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; C-Reactive Protein; Colore | 2014 |
A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2014 |
Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Respo | 2013 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deo | 2014 |
Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final r
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2014 |
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2015 |
[Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; Female; | 2014 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administ | 2014 |
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2015 |
A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplas | 2015 |
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease- | 2015 |
The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2015 |
Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2015 |
Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans | 2015 |
Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2015 |
A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Dise | 2015 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2015 |
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal | 2015 |
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug Combinations; | 2015 |
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2016 |
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2016 |
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neo | 2016 |
Genome-wide DNA Copy-number Analysis in ACTS-CC Trial of Adjuvant Chemotherapy for Stage III Colonic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Chemot | 2016 |
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2016 |
Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA Mismatch Repair; Female; Genes, ras; | 2016 |
Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug C | 2016 |
Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2016 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2016 |
A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug | 2016 |
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diseas | 2016 |
Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2016 |
Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvan | 2016 |
Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2017 |
Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Femal | 2008 |
Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2008 |
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect | 2009 |
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2009 |
Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih | 2009 |
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neop | 2008 |
Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptot | 2009 |
Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Com | 2009 |
A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2009 |
A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2009 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2009 |
[Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antimetabolites, Antineoplast | 2009 |
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2009 |
Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; | 2009 |
Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2009 |
Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2010 |
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2011 |
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2011 |
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2011 |
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2011 |
Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2011 |
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Re | 2012 |
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2011 |
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplas | 2012 |
[Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Col | 2011 |
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2012 |
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptoth | 2012 |
Feasibility study of S-1 adjuvant chemotherapy in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2013 |
Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Surv | 2012 |
Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, | 2013 |
Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2012 |
Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study)
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal | 2013 |
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; | 2013 |
Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2002 |
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorecta | 2002 |
Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2001 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2003 |
Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; C | 2003 |
Pre- and post-operative adjuvant chemotherapy in colorectal cancer.
Topics: Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Mid | 2003 |
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Dihy | 2003 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2004 |
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2004 |
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2004 |
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2004 |
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2004 |
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2004 |
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2004 |
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2004 |
A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2004 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2004 |
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ad | 2004 |
Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combi | 2005 |
Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cross-Over Studie | 2005 |
Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cyclooxygenase 2; Drug Combinations; Fe | 2005 |
Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2005 |
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
[Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronothe | 2005 |
Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2005 |
Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2005 |
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD11b Antigen; CD57 Antigens; CD8 Antig | 2006 |
[Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chem | 2006 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
[Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal | 2006 |
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2006 |
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2007 |
Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 2007 |
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2007 |
Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2008 |
Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; An | 2007 |
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Combined Modalit | 2007 |
Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2007 |
Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2007 |
Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2008 |
High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2008 |
Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2009 |
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Color | 1995 |
[Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
[Pharmacokinetic study in biochemical modulation therapy of UFT with leucovorin tablet].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorect | 1995 |
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 1994 |
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1994 |
[The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1994 |
Initial clinical experience with oral ftorafur and oral 6R,S leucovorin in advanced colorectal carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea | 1993 |
[Evaluation of preoperative chemotherapy for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1996 |
Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colore | 1995 |
[Biochemical modulation by leucovorin of the antineoplastic effect of fluorofur in disseminated colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Drug Admini | 1996 |
[Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 1996 |
Advanced colorectal carcinoma: redefining the role of oral ftorafur.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1996 |
Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 1997 |
Phase II study of UFT plus leucovorin in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug Combinations; | 1997 |
UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Leu | 1997 |
Oral tegafur and folinic acid for the treatment of advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Thera | 1997 |
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations | 1997 |
[Study of preoperative combination therapy with UFT + CDDP in patients with gastric and colorectal cancer--concomitant effects based on the thymidylate synthase inhibitory rat].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy | 1997 |
Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorecta | 1997 |
UFT plus leucovorin vs 5-FU plus leucovorin for metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug C | 1997 |
5-FU or UFT combined with leucovorin for previously untreated metastatic colorectal Ca.
Topics: Adult; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combina | 1997 |
A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).
Topics: Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1997 |
Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Colorectal | 1998 |
Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bi | 1999 |
UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 1999 |
Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo | 1999 |
Impact of uracil/tegafur plus oral calcium folinate on resource utilization.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1999 |
UFT plus calcium folinate/irinotecan in colorectal cancer.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Campt | 1999 |
Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1999 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Drug Combinati | 1999 |
[Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm | 1999 |
[Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1999 |
Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Ne | 2000 |
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combi | 2000 |
Efficacy of UFT plus oral leucovorin in advanced colorectal cancer: a multicenter study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Color | 2000 |
Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2000 |
Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Compliance Study Group, Kanagawa, Japan.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2000 |
UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplas | 2000 |
UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Therapy, Com | 2000 |
Impact of UFT on tumoral TS and DPD levels in colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Di | 2000 |
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
UFT plus leucovorin for metastatic colorectal cancer: Japanese experience.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2001 |
Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 2001 |
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coh | 2001 |
Uracil with ftorafur and low dose oral folinic acid in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; | 2001 |
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2002 |
Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorecta | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2002 |
[Multihospital randomized study on pre- and post-operative adjuvant chemotherapy for colorectal cancer (Part 2)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1991 |
[Cooperative study of surgical adjuvant chemotherapy for colorectal cancer (third report): five-year results. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dox | 1991 |
153 other studies available for tegafur and Colorectal Cancer
| Article | Year |
|---|---|
Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, T | 2020 |
[A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neo | 2022 |
A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
Topics: Administration, Oral; Animals; Colorectal Neoplasms; Fluorouracil; Rats; Tegafur; Uracil | 2023 |
N2 Lymph Node Metastasis Is a Useful Predictor of Recurrence in Patients With Stage III Rectal Cancer Undergoing Adjuvant Chemotherapy Using Tegafur-uracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans | 2023 |
Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans | 2023 |
Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report.
Topics: Aged; Asian People; Biopsy; Colorectal Neoplasms; Creatinine; Diabetic Nephropathies; Disease Progre | 2020 |
[Bevacizumab plus UFT Regimen for Four Patients with Stage Ⅳ Colorectal Cancer Receiving Hemodialysis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Leu | 2020 |
Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2021 |
Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chroma | 2021 |
Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit | 2017 |
Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Co | 2017 |
[Chemoradiotherapy with S-1 for Recurrence Cases of Colorectal Cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Colorectal Neoplasms; Disease Progression; Drug | 2018 |
Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2019 |
Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD3 Co | 2019 |
Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine | 2013 |
Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2013 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2014 |
Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Administrati | 2014 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2014 |
Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemothe | 2013 |
Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2015 |
Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2014 |
Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Col | 2014 |
[Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Hum | 2014 |
[Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
[Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxaliplatin - A Case Report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2015 |
[Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2016 |
Comment on "Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer." Is it cost effectiveness?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Organopl | 2016 |
Prediction of Early Recurrence After Curative Resection of Colorectal Liver Metastasis and Subsequent S-1 Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Colorectal Neoplasms; Drug Combination | 2016 |
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; C | 2016 |
Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; C | 2017 |
Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M | 2008 |
[Three cases of complete response after treatment with UFT and leucovorin for recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne | 2008 |
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2009 |
Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2009 |
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; | 2009 |
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2009 |
Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; D | 2009 |
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2009 |
[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Age Factors; Aged; Antineoplastic Combined Chemothe | 2009 |
CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Island | 2010 |
Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined | 2010 |
Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2010 |
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Humans; Oxonic Acid; Tegafur | 2011 |
[Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Digestive System Neoplas | 2010 |
[Compliance of oral UFT plus leucovorin adjuvant chemotherapy in patients who underwent curative resection for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2010 |
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Gene Frequency; Glucuronosyltr | 2011 |
Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Dis | 2010 |
S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Com | 2010 |
[European Organization for Research and Treatment of Cancer QLQ-C30 and functional assessment of cancer therapy- general for measurement of quality of life in colorectal cancer patients who received adjuvant chemotherapy- a comparison].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2010 |
Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Camptothecin; Cohort Studies; Colorectal Neoplasms; Drug Combinations; Female; Follow-U | 2011 |
Letter to the editor: "Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer".
Topics: Aged; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dru | 2011 |
Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Prolifera | 2011 |
[Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2010 |
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2011 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2012 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2011 |
Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy P | 2012 |
Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2012 |
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2012 |
Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy | 2012 |
S-1 in colorectal cancer: a new standard of care?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; D | 2012 |
Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell L | 2012 |
Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplas | 2013 |
[Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; Female; | 2012 |
Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Of what value is uracil/tegafur plus leucovorin to colorectal cancer patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Approval; Health Services | 2002 |
[5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplati | 2002 |
A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Canada; Clinical Trials, Phase III as T | 2003 |
Oral tegafur-uracil plus leucovorin in metastatic colorectal cancer: clinical insights. Proceedings of a roundtable expert meeting. October 2002, Nice, France.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Leucovorin; | 2003 |
[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh | 2003 |
Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 18; Colorectal Neoplasms; DNA | 2004 |
[Clinical significance of TS and DPD activities in colorectal carcinoma as a predictive factor of UFT sensitivity].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Apoptosis; Chemotherapy, Adjuvant; Colorectal Neoplasms | 2004 |
[Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administration | 2004 |
[Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh | 2004 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colorectal Neopl | 2004 |
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans; Neoplasm Staging; Proteoglycans; Tegafur; Urac | 2004 |
[Variation of cytokines with administration of chemotherapeutic and immuno-therapeutic drugs for colorectal cancer].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cytoki | 2004 |
[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2004 |
Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combi | 2005 |
[Case reports of use of TS-1 for second/third-line chemotherapy for advanced colorectal carcinoma].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch | 2005 |
[Combined chemotherapy with oral leucovorin (LV) + tegafur/uracil (UFT) and hepatic arterial infusion (HAI) therapy for liver metastasis of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2005 |
The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2006 |
[Usefulness in predicting parameters for the selection of responders who received immunochemotherapy with PSK in patients with colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; CD4-Positive T-Lymphocytes; Colorectal | 2005 |
[Hepatic arterial infusion (HAI) chemotherapy achieved a complete response (CR) for multiple liver metastases of colorectal cancer--two case reports].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2005 |
[Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials | 2005 |
The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2006 |
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2006 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2006 |
[Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplas | 2006 |
Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 2006 |
Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2007 |
[Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diet; Disease Models, | 2007 |
[Second-or third-line chemotherapy with CPT-11+TS-1 for 5 cases of metastatic and recurrent colorectal cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2007 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2007 |
Combination therapy of S-1 and CDDP for patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2007 |
Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2007 |
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2007 |
[Two cases of recurrent colorectal cancer treated successfully with folinate/tegafur/uracil (UFT/LV) chemotherapy on an outpatient basis].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal | 2008 |
The number of 5-fluoro-2'-deoxyuridine-5'-monophosphate binding sites and reduced folate pool in human colorectal carcinoma tissues: changes after tegafur and uracil treatment.
Topics: Base Sequence; Binding Sites; Colorectal Neoplasms; Fluorodeoxyuridylate; Humans; Molecular Sequence | 1995 |
[Portal-transfer of an orally administered anti-cancer agent analysis of the time course of portal blood and systemic blood levels of preoperatively administered UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 1994 |
[Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pr | 1993 |
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1993 |
[Changes of the number of FdUMP binding sites of thymidylate synthase and folate pools in human colorectal carcinomas following the administration of tegafur and uracil: preliminary report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Colorectal Neoplasms; Fluorodeoxyurid | 1993 |
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Topics: Animals; Carcinoma; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Synergism; Enzyme | 1995 |
[Evaluation of subrenal capsule assay (SRC) for clinical cancers].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 1996 |
Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; | 1997 |
Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Differentiatio | 1997 |
A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America.
Topics: Argentina; Brazil; Chemotherapy, Adjuvant; Colorectal Neoplasms; Costs and Cost Analysis; Drug Combi | 1997 |
[Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H | 1998 |
5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
Topics: Animals; Body Weight; Colorectal Neoplasms; Female; Fluorouracil; Leucovorin; Metabolic Clearance Ra | 1995 |
Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; | 1998 |
Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1998 |
Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Disease Models, Animal; Drug Combin | 1999 |
[Tegafur/uracil and oral calcium folinate in colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Humans; Tegafur; Uracil | 1998 |
Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Clinical Trials as Topi | 1999 |
[Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Colorectal Neoplasms; Drug Administrati | 1999 |
[UFT-E granule compliance in postoperative adjuvant chemotherapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associate | 2000 |
Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colorectal Neoplasms; Drug C | 2000 |
A novel weekday-on/weekend-off UFT schedule.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2001 |
A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; D | 2001 |
Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Patient preference for oral chemotherapy].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Capsule instead of infusion--new oral chemotherapy option].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1992 |
Chemotherapy for colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Colorectal Neopl | 1992 |
[Electron microscopic study on the method of evaluation of SRC assay].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Evaluation | 1992 |
Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
[The usefulness of UFT administration in colorectal cancer with emphasis on postoperative administration (Part 3)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1991 |
[Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colon; Colorectal Neoplasms; | 1991 |
[Relationship between antitumor activity and the inhibition of thymidylate synthase after oral administration of UFT in nude mice bearing human tumor].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cel | 1990 |
Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.
Topics: Administration, Oral; Adult; Aged; Colorectal Neoplasms; Drug Evaluation; Female; Humans; Male; Midd | 1990 |
[Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Colorectal Ne | 1990 |
[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1990 |
Phase II trial of UFT in advanced colorectal and gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1990 |
[Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration].
Topics: Colorectal Neoplasms; Combined Modality Therapy; Delayed-Action Preparations; Fluorouracil; Humans; | 1990 |
[Plasma and tissue concentration of tegafur by a new soft capsule type suppository in colorectal carcinoma].
Topics: Aged; Aged, 80 and over; Capsules; Colorectal Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; | 1989 |
[Effects of neo-adjuvant chemotherapy with UFT (a combination of tegafur and uracil) on DNA-synthesizing enzyme activities in human colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Depression, Chemical; Humans; | 1989 |
[Effect of UFT on nuclear DNA distribution of gastric and colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA, Neoplasm; Humans; Stomach | 1989 |
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Colorectal Neoplasms; Floxuridine; Fluor | 1988 |
[Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Postoper | 1988 |